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Abstract  
The cure of cancer represents an ultimate challenge for scientists from different fields. 
Cancer complexity and diversity hamper the discovery of a broadly applicable treatment, 
and consequently, cancer represents the second cause of premature death worldwide. 
Despite the continuous approval of new drugs, the cancer burden keeps increasing due to 
different factors and leaves a vast number of patients helpless. Conventional 
chemotherapy still represents the backbone of cancer medical care. However, these agents 
are not able to selectively accumulate at the disease site which limits their efficacy and 
cause severe side effects. In the last years, targeted therapy has appeared as an innovative 
approach to overcome the drawbacks shown by traditional chemotherapeutics. In this 
approach, a cytotoxic agent is directed to the tumor site through the covalent conjugation 
to homing devices (e.g. antibodies, small molecules).  
Cryptophycins are cyclic depsipeptides with natural origin that present high cytotoxicity 
against several cell lines. Although cryptophycins cannot be used as stand-alone agent 
due to their side effects, they hold great potential as cytotoxic agent for tumor targeted 
therapy. Therefore, the discovery of new cryptophycins that can be conjugated to homing 
devices and their vectorization could be translated in a significant therapeutic activity.  
In the first part (chapter 3), the discovery of new cryptophycin analogues that retain the 
high cytotoxicity of the parent compound and present a functional group that can be used 
for conjugation to a delivery vehicle was described. Moreover, the usage of molecular 
dynamics to predict the biological activity of new analogues was explored.  
The second part (chapters 4 and 5), describes the usage of cryptophycin-55 glycinate as 
payload in small molecule-drug conjugates (SMDCs). In chapter 4, the payload was 
conjugated to a ligand capable to target the carbonic anhydrase IX, a transmembrane 
enzyme that is widely overexpressed in tumors. The cytotoxic activity of the resulting 
conjugate was studied in vitro, and the therapeutic activity was investigated in mice. In 
chapter 5, the payload was further explored by coupling it to a cyclic peptide targeting 
the somatostatin receptor 2, a marker which is commonly overexpressed in 
neuroendocrine tumors. The cytotoxicity of the conjugates was evaluated in a cell-based 
assay. In this case, further investigations in their targeting properties and stability were 
performed. Finally, the antitumor activity of the lead compound was investigated in vivo. 
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1.1 Cancer and chemotherapy  
Despite the continuous development of new and more efficient treatments, cancer remains 
the second cause of premature death worldwide.[1] According to a report from the World 
Health Organization (WHO), this disease caused approximately 8 million fatalities in 
2012 and this number is expected to increase up to 9.6 million in 2018.[2] The prediction 
for the next decades is not better with a continuous increase of cases and deaths. The main 
reasons of this unceasing escalation are the steady population growth, ageing, and the 
increase of risk factors (e.g. tobacco use, unhealthy diet, lack of physical activity). 
Cancer cannot be understood as one single disease but as a complex group of diseases 
which have in common the abnormal cell division without control that can invade nearby 
tissues and, if not treated, lead to the death of the host.[3] The high diversity between 
cancer types is the reason that incidence and mortality are not directly related (Figure 1). 
While lung and prostate cancer are prevalent in men, mortality of lung cancer is circa 
three times higher. A similar situation is found in women: albeit breast cancer is three 
times more incident than colorectum, the mortality differs in less than two-fold.   
 
Figure 1. Estimated age-standardized (World) cancer incidence and mortality rates (ASR) per 100 000, by 
majors sites, in both genders, 2012.[1] 
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The heterogeneity of cancer makes treatment even more challenging. However, in all 
cases regular care is based on the surgical removal of the tumor, when this is possible, 
radiotherapy, and chemotherapy. Conventional chemotherapy consists in the 
administration of small cytotoxic agents that aim cell death by affecting fundamental 
cellular processes such as cell division.[4] This strategy was first coined by the Nobel 
laureate Paul Ehrlich in the early 1900s and reached a substantial milestone in 1949 with 
the first chemotherapeutic to receive Food and Drug Administration (FDA) approval. 
More than half century later the concept is still valid, and many new treatments have 
appeared. The classical categorization of chemotherapeutics is based on their mechanism 
of action and can be subdivided in different groups (Figure 2).[5] 
 DNA alkylating agents[6] were the earliest drugs to be developed, being 
mechlorethamine the first chemotherapeutic agent to be approved for cancer 
treatment. Its activity relies in the presence of highly electrophilic groups which can 
be attacked by the N7-position of guanine bases and crosslink the DNA strands 
blocking their replication. The high reactivity of mechlorethamine prevents oral 
administration and for this reason, derivatives such as chlorambucil (FDA approved 
in 1957) and cyclophosphamide (1959) were developed. 
 Although their mode of action relies in the formation of metal adducts with DNA 
instead of the previously described alkylation of DNA, platinum complexes can be 
also included in this group. The serendipitously discovery of cisplatin, approved in 
1978, was of high relevance and opened the research field of platinum complexes 
such as carboplatin (1989) and oxaliplatin (2002).[7] Nowadays, they play an essential 
role in the treatment and there is a high interest on discovering new analogues.[8]  
 Antimetabolites were the next compounds to be developed. This class of compounds 
is able to mimic essential cellular molecules and interferes with the DNA by 
competing with the natural substrate.[6] Methotrexate (1953) and 5-fluorouracil (1962) 
are the most important examples of antimetabolites. The first one was inspired in the 
observation that folic acid plays an essential role in tumor growth and thus, folate 
antagonists could have antitumor properties. The second one, is the result of adding a 
fluorine in the C5-position of the essential nucleobase uracil.  
 Antibiotics with antitumor activity were first identified on a program related to the 
second world war and they can show different mechanisms of action. Dactinomycin 
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(1964) is one compound from this class.[9] The anthracyclines were also first classified 
in this group but are better regarded as topoisomerase inhibitors.[10] 
 Topoisomerase inhibitors block the changes in DNA structure by interfering with 
the topoisomerase enzyme (I and II) which catalyzes unravelling of DNA double 
strand for replication. Topoisomerase enzyme I initiates the cleavage of one DNA 
strand while topoisomerase enzyme II cleaves both DNA strands.[11] Camptothecin 
and their analogues act as topoisomerase I inhibitors while the anthracyclines such as 
doxorubicin (1974) are topoisomerase II inhibitors.  
 Mitosis inhibitors include vinca alkaloids and taxanes.[12,13] Microtubules are an 
essential part of the cytoskeleton, which plays a substantial role in cell division. By 
interfering with their dynamics, the cell is no longer able to divide and initiates 
apoptosis. Vinca alkaloids such as vinblastine (1965) prevent the polymerization of 
tubulin into microtubules. On the other hand, taxanes like paclitaxel (1992) present a 
different mode of action. They stabilize microtubule and block their disassembly 
impeding the formation of free tubulin. 
 
Figure 2. Structures of traditional chemotherapeutic agents classified by their mode of action. 
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Chemotherapeutics, administered as single agent or in combination with radiotherapy and 
surgery, have certainly contributed to decline the cancer mortality rate. Nevertheless, 
complete and durable cure remains the exception rather than the rule. The main reason 
for the lack of efficacy, especially in metastatic cancer, is that anticancer drugs lack tumor 
preference and affect healthy tissues.[14] As a consequence, chemotherapeutics display a 
narrow therapeutic window, which can be described as the dosage range of a drug that 
can treat the disease effectively without displaying harsh side effects. In order to have 
efficacy, anticancer drugs are administered near the maximum tolerated dose (MTD) 
which results in severe side effects (e.g. bone marrow suppression, nausea, hair loss).[15] 
In another early vision from Paul Ehrlich, the idea of a “magic bullet” was conceived. An 
agent that could specifically attack the disease without harming the rest of the tissues 
would constitute and ideal drug that he named Zauberkugel, the magic bullet. This early 
vision was fulfilled more than 20 years ago with the discovery (1996) and later FDA 
approval of imatinib (2001), a tyrosine kinase inhibitor. Since then, targeted therapy has 
emerged as a promising approach to overcome the limitations observed by traditional 
chemotherapeutics and enhance their effectivity.  
 
1.2 Targeted therapy 
In the last years, research on cancer therapy has experienced a shift from discovery of 
cytotoxic agents to targeted therapy.[16] The better understanding of the mechanism of 
cancer and its hallmarks have provided knowledge to develop efficient targeting 
systems.[17,18] For example, the observation that tyrosine kinases have an abnormal 
function in most of cancers prompted the development of multiple tyrosine kinase 
inhibitors.[16] Another approach is based on the conjugation of cytotoxic agents to carriers 
that will selectively deliver the compound to the disease site. The targeting can be 
mediated by two different mechanisms: passive or active.[19] 
Passive targeting is based in the enhanced permeability and retention (EPR) effect.[20] 
Due to the lack of effective lymphatic drainage and other disorders in tumors, large 
molecules (e.g. liposomes, nanoparticles) are directed towards the tumor tissue in a bigger 
extend than to the healthy one. Successful examples of passive targeting can be found in 
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the liposomal formulation of doxorubicin (Caelyx™)[21] or the albumin-bound paclitaxel 
(Abraxane™).[22]  
On the other hand, the overexpression of different receptors in tumors can be used for 
active targeting. In this approach, a targeting molecule (e.g. antibody, peptide, 
peptidomimetic) is covalently attached to a cytotoxic agent. The conjugation is done 
through a linker that allows good plasma stability and efficient drug release at the tumor 
site due to the higher presence of certain enzymes or physiological conditions. Once the 
payload is released from the conjugate, it recovers its original potency and induces 
apoptosis of the tumor cells (Figure 3).[23–25]  
 
Figure 3.  Mechanism of action in active tumor targeting approach. 
Two main approaches are used to increase the therapeutic window of this class of 
compounds. The first one, consists in the discovery of new homing devices which 
recognize a specific antigen with exquisite selectivity and thus, increases the MTD of the 
conjugate. On the other hand, the research of new cytotoxic agents with increased potency 
contributes to reduce the minimum effective dose (MED). An ideal system would 
combine both techniques to enhance the therapeutic window as much as possible to have 
better chances of success.  
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Active targeting represents the cornerstone of current research in targeted therapy. 
Hundreds of products are currently in clinical trials and many more are in the research 
pipeline of the most important pharmaceutical companies worldwide.[26]  
The next sections will be exclusively focused on active targeting using antibodies or small 
molecules as targeting moieties, different type of linkers and payloads.  
 
1.2.1 Antibody-Drug Conjugates (ADCs) 
Antibodies, also called immunoglobulins (Igs), are large Y-shaped proteins consisting of 
four polypeptides, two identical light chains and two identical heavy chains, which are 
connected via disulfide bridges. Their production by the plasma cells enables the immune 
system to neutralize pathogens that could harm our body (e.g. bacteria, viruses) as they 
are able to recognize antigens with excellent specificity. These characteristics promoted 
the development of antibodies targeting certain antigens which are overexpressed in 
cancer cells.  
The first antibodies were produced by vaccinating mice with a target antigen that 
stimulated the production of specific antibodies in the sera. Nevertheless, this procedure 
led to a mixture of antibodies, some of them being nonspecific, in poor yields. Seeking 
for a better methodology, Köhler and Milstein developed in 1975 the hybridoma 
technology, which was later awarded with the Nobel prize in physiology or medicine in 
1984.[27] In this technique, antibody-producing B cells from the spleen of a mice are 
isolated and fused with tumor cells resulting in hybridoma cells. These hybridoma cells 
can be then cultured in vitro to produce large amounts of the same monoclonal antibody 
(mAb) which can be used to treat different diseases. In cancer treatment, they can trigger 
an immune system response and are able to induce cancer cell death through different 
mechanisms.[28] 
However, after the first clinical trials in 1980, several drawbacks were observed. The 
murine origin of the mAbs produced an immune response resulting in a rapid clearance 
from the circulation. Modifications of the mAb through recombinant DNA technology 
resulted in the production of “chimeric” antibodies, in which some sequences of the 
mouse antibody were replaced by naturally occurring sequences in human antibodies 
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(Figure 4). The specific binding of the antibody was retained but chimeric antibodies 
contained a significant number of murine residues. Further development made possible 
the production of “humanized” antibodies, where only the indispensable complementary 
determining regions (CDRs) responsible for antigen recognition were from mouse origin. 
The continuous advancement of antibody engineering with the introduction of phage 
display technology, recently awarded with the Nobel prize in chemistry 2018 to George 
Smith and Sir Gregory Winter, and the usage of transgenic mice led the obtention of 
human antibodies. These products showed reduced or null immune response and the 
circulatory half-life was prolonged up to three weeks, an enormous extension when 
compared to murine antibodies (typically two to three days).  
 
Figure 4. Representation of mouse, chimeric, humanized and human antibodies. Mouse fragments are 
represented in green and red while human fragments are represented in blue. The antibody subdomains are 
shown: fragment antigen binding (Fab), fragment crystallizable region (Fc), fragment variable domain (Fv), 
heavy-chain variable (VH), heavy-chain constant (CH), light-chain variable (VL), light-chain constant (CL) and 
complementary determining regions (CDRs).  
All the efforts in the field were compensated with the FDA approval of the first antibody 
for the treatment of cancer, rituximab (1997) a chimeric antibody for the treatment of 
non-Hodgkin’s lymphoma. This accomplishment was successively followed by 
alemtuzumab (2001) and ofatumumab (2009). Despite the undeniable step forward of 
cancer treatment using antibodies, the therapeutic activity in solid tumors was modest at 
best and the treatment had to be combined with chemotherapeutic agents. Moreover, only 
two cell-surface receptors (HER2 and EGFR) were successfully targeted to treat solid 
tumors.  
With the need to improve the therapeutic window of many cytotoxic agents and the clear 
evidences that antibodies could selectively recognize certain antigens from cancer cells, 
it appeared the idea to arm antibodies with payloads to create antibody-drug conjugates 
(ADCs).[29] The mechanism of action of ADCs is based on Figure 3, a mAb recognizes 
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and binds an antigen that is overexpressed on the cancer cell surface. Then, the fused 
ADC-antigen undergoes internalization via receptor-mediated endocytosis. Through this 
route, the complex ends up in endosomes, which are responsible for two crucial steps. On 
the one hand, the antigen is recycled and transported back to the cell surface. On the other 
hand, it transports the ADC to the lysosome. In this compartment, the ADC undergoes 
different degradation pathways to release the cytotoxic agent in its unimpaired potent 
form. The complexity of ADCs arises the necessity of a multiparameter optimization from 
the three components (antibody, linker, and cytotoxic agent) in order to increase the 
possibilities of clinical success.[30] 
The first generation of ADCs was devoted to provide tumor selectivity of traditional 
chemotherapeutics.[31] The best example from this class of compounds is an ADC that 
resulted from the conjugation of doxorubicin to the chimeric antibody BR96, which 
targets the Lewis-Y antigen. This conjugate was the only one from its class that reached 
phase II human clinical trial, but the limited antitumor activity in metastatic breast cancer 
and the observed toxicity in the gastrointestinal tract halted its development.[32] The early 
clinical failure from the first ADCs lowered the initial enthusiasm that was generated in 
this challenging research area. However, deep analysis of the mistakes that were made 
established the basis for the development of efficient ADCs.[33]  
 First, the usage of a chimeric antibody resulted in a considerable immunogenic 
response, an important aspect to be considered in the next generation of conjugates 
that could be solved adopting humanized or human immunoglobulins as targeting 
devices. 
 Second, the acid-labile hydrazone linker that was chosen to connect the antibody to 
the drug was unstable under physiological conditions showing a slow release of the 
drug which resulted in a lower therapeutic index and systematic toxicity. The design 
of new linkers should find a balance between good plasma stability and efficient 
intracellular drug release.[34] 
 Third, traditional cytotoxic agents were lacking potency to produce antitumor activity 
due to distinct uptake mechanisms. Based on different experiments, it was predicted 
that drugs with picomolar activity are required, which opened a new field of research 
of more potent payloads. 
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 Finally, the drug-to-antibody ratio (DAR) affects the potency and pharmacological 
properties. In general terms, higher DAR leads to increased in vitro potency but to 
unfavorable biodistribution and pharmacokinetics.[35] Although it has been recently 
reported that a higher DAR can be beneficial when the hydrophobicity is reduced,[36] 
the first generation of ADCs suffered from an overloaded antibody.   
With all the previous considerations in mind, a second generation of ADCs was generated. 
As a result, four conjugates have received FDA approval (Figure 5).  
 
Figure 5. Molecular structures of the currently FDA approved ADCs.  
Mylotarg™ (14, Figure 5) was the first ADC to receive FDA approval in 2000 for the 
treatment of acute myeloid leukemia.[37] Due to its accelerated approval, a postmarketing 
clinical trial was done with an unexpected outcome. It was not possible to confirm a 
therapeutic benefit in the treatment group and, moreover, a slight increased treatment-
related mortality was observed. As consequence, the drug was withdrawn from the market 
in 2010. However, subsequent trials with lower doses and fractioned regimens resulted in 
the long-awaited reapproval in 2017.[38] More than ten years after the first ADC approval, 
Adcetris™ (15, Figure 5) was approved in 2011 for the treatment of relapsed Hodgkin 
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lymphoma and systematic anaplastic large cell lymphoma.[39] Only two years later, in 
2013, Kadcyla™ (16, Figure 5) was approved for treating  HER2 positive breast 
cancer.[40] Besponsa™ (17, Figure 5) is the most recent example of success in this field 
with its approval in 2017 for the treatment of acute lymphoblastic leukemia.[41]  
The success of the first ADCs raised the interest in this area of research and many 
companies introduced them in their pipelines.[42] As a result, about 60 products are 
currently in different stages of clinical trials and many more are in the preclinical 
phase.[43] However, this technology is far from being optimal and presents several 
drawbacks to take into account.[44]  
 Due to its large size, antibodies present a poor penetration in solid tumors and the 
long circulatory half-life can produce side effects due to premature payload release. 
 Although the usage of human antibodies has dramatically reduced the 
immunogenicity, an immune response can still be triggered upon long treatments and, 
as a result, the efficacy gets compromised.  
 The products obtained using traditional thiol-maleimide strategy are heterogeneous 
mixtures of compounds with different DAR. The properties of them varies drastically 
and the purification to obtain a homogenous product is challenging. The site-specific 
conjugation has appeared as a new approach to overcome this problem but the 
technology is still under development.[45,46]  
 Finally, the large-scale production of ADCs is challenging, as it requires 
simultaneously the usage of sterile conditions and safety precautions due to the high 
cytotoxicity. As a result, this class of compounds presents high cost-of-goods which 
limit their development and increase the costs of the treatment.  
Moreover, the mechanism of action is not yet fully understood. A special mention 
regarding the requirement of internalization for anticancer efficacy needs to be done. 
While it was generally accepted that active targeted therapy activity relies on the efficient 
internalization of the construct, it has been recently proven that non-internalizing 
compounds can display potent and selective antitumoral activity.[47–52] In this case, upon 
binding of the antibody to the desired antigen, the drug is released in the tumor 
microenvironment and the drug effects its cytotoxicity by the so-called bystander effect. 
Chapter 1 
29 
 
With all these limitations, there is a strong motivation to explore alternative homing 
devices which may be easier to produce and can reach diseased cells more efficiently.  
 
1.2.2 Small Molecule-Drug Conjugates (SMDCs)  
Small molecules (e.g. peptides, peptidomimetics) have emerged as a promising 
alternative to antibodies as homing devices.[53–57] Their smaller size renders a better 
extravasation and penetration in the tumor. Moreover, the conjugation chemistry used to 
produce small molecule-drug conjugates (SMDCs) leads to defined molecular structures 
that can be easily purified and characterized. This characteristic also allows a hit-to-lead 
optimization and dramatically reduces the production costs when compared to ADCs. 
Another advantage of SMDCs is their lack of immunogenicity. 
The biggest difference between ADCs and SMDCs is their pharmacokinetics. While 
ADCs remain in circulation up to one week, SMDCs are readily cleared through the 
kidneys and usually display half-life shorter than one day. Although ADCs can display 
activity via EPR effect, the rapid pharmacokinetics of SMDCs allows higher payload 
concentration in the tumor tissue and reduce the side effects to other organs (Figure 6).[58] 
Nevertheless, due to its faster pharmacokinetic profile, SMDCs may require more 
frequent dosing.  
 
Figure 6. Schematic illustration of the potential mechanistic and pharmacokinetic differences between an 
ADC and a SMDC.[58] 
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Despite all the advantages of small molecules as targeting moieties compared to 
antibodies, their clinical application has not been proven yet. One may attribute that to 
several reasons. On the one hand, peptides usually suffer from short plasma half-life as a 
result of their fast clearance and poor stability against proteases. However, the progress 
in the field has minimized the problem using different methods such as cyclization, N-
methylation or the introduction of D-amino acids.[59] On the other hand, while antibodies 
can be virtually generated against any antigen, peptide targeting remains limited to a small 
number of targets. Among the antigens that have been successfully targeted with small 
molecules, the Folate Receptor (FR), the Prostate-Specific Membrane Antigen (PSMA), 
the Somatostatin Receptors (SSTRs) and Carbonic Anhydrase IX (CAIX) have received 
most of the attention and will be described in the following sections. More recently, other 
receptors (e.g. the biotin receptor, bombesin receptor, Eph receptor) have gained attention 
as they can be potentially targeted with small molecules. In this direction, Bicycle 
Therapeutics have made excellent progress discovering bicyclic peptides targeting 
different receptors using phage display techniques. The compound named BT1718, a 
bicyclic peptide targeting the membrane type 1 matrix metalloproteinase (MT1-MMP) 
conjugated to DM1, is their lead molecule and is currently being evaluated in a phase I/IIa 
clinical trial. Moreover, with the growing interest in this field, the development of phage 
display techniques, and the increasing knowledge in the design of ligand-targeted cancer 
therapeutics, it is expected that many receptors can be targeted in the future using small 
molecules.[60,61]  
 
1.2.2.1 SMDCs targeting the folate receptor (FR) 
Larger amounts of vitamins are required to sustain the fast-growing rate of cancer cells. 
To fulfill their needs, certain tumors overexpress vitamin receptors and this expression 
level increases in advanced stage of the disease. Among them, the folate receptor (FR) 
has received most of the attention and several compounds primarily developed by 
Endocyte have entered clinical trials. Folic acid, also known as folate or vitamin B9, has 
shown optimal properties as targeting moiety for the folate receptor. Its high binding 
affinity (Kd = 1-10 nM) and easy functionalization allowed the construction of conjugates 
for diagnosis and therapeutic purposes.[62,63]   
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The first compounds using folate as targeting moiety were devoted to imaging purposes. 
Etarfolatide (16, Figure 7) was one of the first products of its class that reached clinical 
trials. The molecule consists in the conjugation of folate to an imaging agent based on 
technetium-99m which has been used in different clinical stages to identify FR positive 
patients.[64,65] Folate-fluorescein, better known as EC17 (17, Figure 7), was also 
developed for diagnosis purposes and has been used for intraoperative tumor removal.[66] 
With the successful identification of FR positive tumors using several imaging 
conjugates, different SMDCs employing folate as targeting moiety have been reported.[67] 
 
Figure 7. Molecular structures of folate conjugates for imaging or therapeutic purposes.  
The most studied SMDC using folic acid as delivery vehicle is vintafolide (18, Figure 7), 
a conjugate containing desacetylvinblastin hydrazide (DAVLBH) as drug.[68,69] First 
developed by Endocyte and later licensed to Merck in an operation worth up to $1 billion, 
it reached phase III clinical trials for platinum-resistant ovarian cancer. However, the 
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results of the clinical trials, reported shortly after the European Medicines Agency (EMA) 
had recommended the drug approval, halted its development. With the recent setback of 
vintafolide, the efforts of Endocyte are now focused on novel conjugates bearing different 
payloads such as tubulysin (19, Figure 7), currently in clinical trials phase I, or 
pyrrolobenzodiazepines.[70,71] 
 
1.2.2.2 SMDCs targeting the Prostate-Specific Membrane Antigen (PSMA) 
Prostate cancer (PCa) represents the second most prevalent cancer among men 
worldwide. The prostate-specific membrane antigen (PSMA) is a specific marker used 
for the diagnosis of PCa because its concentration is elevated in case of prostate disorders. 
Moreover, this glycoprotein is overexpressed in the cell surface of prostate cancer cells 
and represents an interesting dartboard to be targeted.[72] Interestingly, the expression 
levels are further enhanced with cancer aggressiveness and metastasis. The 2-[3-(1,3-
dicarboxypropyl)ureido]pentanedioic acid (DUPA) motif and several derivatives have 
high binding affinity to PSMA and can be used for targeting purposes. Like in the folate 
receptor field, most of the advances and clinical trials have been reported by Endocyte. 
More recently, Heidelberg Pharma has also entered in this research area developing ADCs 
and SMDCs targeting PSMA. 
One of the first compounds to be developed used the metastable nuclear technetium-99m 
for the diagnosis of PSMA positive tumors (20, Figure 8).[73] More recently, the 
conjugation of a DUPA analogue to the cytotoxic agent tubulysin led to EC1169 (21, 
Figure 8), which showed good in vivo activity in mice and has been tested in clinical trial 
phase I although no results have been reported so far.[74] The most promising PSMA 
targeting compound, Lu-PSMA-617 (22, Figure 8) was developed by Endocyte and is 
currently in clinical trial phase III. The therapeutic activity of this compound relies on the 
β-particle radiation emitted by Lutetium-177 which causes cell death. Due to the well 
defined range of action of these particles (1 mm), only cancer cells expressing PSMA are 
affected and side effects to other tissues are reduced.[75] Moreover, the efficacy of this 
compound has been enhanced with the incorporation of several albumin-binding motifs 
(23, Figure 8) to increase the circulatory half-life, although only preclinical data is 
available.[76,77]   
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Figure 8. Molecular structures of conjugates targeting the PSMA receptor. 
 
1.2.2.3 SMDCs targeting Carbonic Anhydrase IX (CAIX) 
The fast metabolism of tumors to sustain the uncontrolled proliferation of cancer cells 
leads to acidic microenvironment and hypoxic regions.[55] Carbonic anhydrases (CAs) are 
transmembrane zinc metalloenzymes responsible to catalyze the reversible hydration of 
carbon dioxide to hydrogen carbonate and proton (CO2 + H2O ↔ HCO3- + H+).[78] Their 
most important function is to maintain the acid-base balance and to transport carbon 
dioxide out of the tissues. As a consequence, two from the fifteen known isoforms of 
carbonic anhydrase, CA9 and CA12, are overexpressed in many tumors. Carbonic 
anhydrase IX (CAIX) is the most strongly overexpressed gene in response to hypoxia in 
cancer cells and is a marker for unfavorable prognosis.[79] Moreover, its expression in 
healthy tissues is limited to low levels in the gastro-intestinal tract making it an exquisite 
marker for targeted therapy.   
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In the last years, several advances have been made by Neri and co-workers from Philogen, 
and more recently Endocyte has entered this field as well. A first and prominent milestone 
was the discovery that an acetazolamide derivative can efficiently target CAIX.[80] This 
moiety was used to create SMDCs using duocarmycin derivatives or mertansine (DM1) 
as cytotoxic agents and produced a significant tumor growth delay in nude mice. More 
interestingly, the acetazolamide moiety has been labeled with technetium-99m for 
diagnosis purposes and the obtained compound (24, Figure 9) is currently entering 
clinical trials phase I.[81]  
 
Figure 9. Molecular structures of conjugates targeting the CAIX enzyme.  
With the basis established, the conjugates were further improved by studying different 
payloads and optimizing the linker to be used in order to obtain an efficient release of the 
cytotoxic agent and avoid side effects.[82,83] Further improvements of the targeting 
properties were achieved using different methods. The usage of a bivalent acetazolamide 
moiety clearly increased the therapeutic activity of previously reported conjugates.[84] 
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Alternatively, dual-display DNA-encoded chemical libraries can identify new fragments 
to increase the binding affinity due to chelate effect. Using this technique, a new fragment 
was discovered and the resulting bidentate ligand displayed an improved binding 
affinity.[85] Employing the maturated acetazolamide moiety and the best linker-drug 
combination from previous publications, a SMDC (25, Figure 9) was prepared.[86] 
Conjugate 25 showed remarkable tumor growth delay and was able to challenge the 
therapeutic efficacy of an ADC targeting the same antigen and employing an equal linker-
drug moiety. Moreover, the compound showed better biodistribution at early time points 
and when combined with interleukin-2 it was able to eradicate cancer in all studied nude 
and immunocompetent mice.[87] 
More recently, the fluorobenzosulfonamide (CAL) moiety targeting CAIX has been used 
to develop a conjugate using tubulysin as cytotoxic agent (26, Figure 9).[88,89] The 
compound exhibited the characteristic non-internalizing properties of CAIX targeting 
conjugates and showed a remarkable tumor growth delay in nude mice.  
 
1.2.2.4 SMDCs targeting Somatostatin Receptors (SSTRs) 
The somatostatin receptors (SSTRs) are a superfamily of G protein-coupled receptors 
which can be subdivided in five subfamilies, SSTR1-SSTR5. The native somatostatin 
(SST) peptide hormone is responsible for the regulation of the neuroendocrine system by 
interacting with the SSTRs. Among other functions, somatostatin is responsible to 
suppress the growth hormone and the insulin secretion.[90]  
Many neuroendocrine tumors overexpress the SSTRs, mainly SSTR2, which could be 
potentially targeted with SST (Figure 10). Unfortunately, somatostatin, which is 
presented in two active forms, sst-14 and sst-28, cannot be used due to its short half-life 
in vivo (2-3 min). However, peptide development allowed the identification of octreotide 
(28, Figure 10), an octapeptide analogue of somatostatin. The incorporation of D-amino 
acids and the downsizing of the peptide dramatically increased the half-life (2 h). 
Moreover, while SST presents high affinity for the five SSTRs subtypes, octreotide shows 
specificity for SSTR2. For all these reasons, octreotide is used to treat acromegaly and 
tumors producing growth hormone and is the third top-selling non-insulin peptide.[91]   
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Figure 10. Molecular structures of somatostatin-14, octreotide, octreoscan, and PEN-221. 
Octreotide conjugates have been largely studied for the diagnosis and therapy of 
neuroendocrine tumors. The most successful example is octreoscan, an indium-111 
radiolabeled octreotide, clinically used for more than 20 years to detect pancreatic 
neuroendocrine tumors (29, Figure 10). More recently, a gallium-68 conjugate showed 
higher sensitivity and resolution to image neuroendocrine tumors compared to octreoscan 
and received FDA approval in 2016. This compound, also named 68Ga-DOTATATE, 
consists of Tyr3-octreotate, a closely related analogue of octreotide containing a 
carboxylic acid at the C-terminus (octreotate) and a tyrosine in the third position of the 
sequence. The DOTA chelator at the N-terminus allows the complexation of gallium-68. 
The same compound but containing the radiotherapeutic lutetium-177 is approved for the 
treatment of SSTR positive gastroenteropancreatic neuroendocrine tumors under the trade 
name Lutathera.[92,93] Octreotide has also been conjugated to a large number of cytotoxic 
agents such as doxorubicin,[94] periplocymarin[95] or paclitaxel.[96] However, none of these 
compounds passed the preclinical evaluation. An exception needs to be mentioned with 
a compound developed by Tarveda Therapeutics named PEN-221 (30, Figure 10), which 
is currently in clinical trial phase 1/2a. This compound combines the targeting properties 
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of an analogue of octreotide with the killing potency of DM1 and it has been able to 
eradicate tumors in different xenograft models.[97]   
 
1.2.3 The linker 
The connection between the targeting moiety and the cytotoxic agent is of high relevance 
as it can dramatically modulate the safety and efficacy of the final construct. An ideal 
linker should present complete stability in circulation and fast degradation in the 
lysosomes or in the proteolytically and physiologically enriched extracellular milieu of 
the tumor. Moreover, the linker usually contains highly hydrophilic moieties to increase 
the water solubility of the final construct. Linkers can be classified into four main groups 
according to their mechanism of release: uncleavable, acid-labile, reducible and enzyme 
sensitive (Scheme 1).[98,99] Another aspect to take into account is the need to include a 
self-immolative spacer to increase the release effectivity in many cases.[100]  
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Scheme 1. Drug release mechanism of active targeting compounds bearing acid-labile (A), reducible (B) or 
enzymatically sensitive (C) linkers. X = NH or O.  
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 Uncleavable linkers are characterized to have very good stability in circulation and 
the release of the drug only occurs in the lysosomes after internalization and 
hydrolysis of the conjugate. Due to their properties, the usage of non-cleavable linkers 
is not recommended in the SMDC field but can be useful in ADC development. 
Indeed, one of the currently approved ADCs, Kadcyla®, has an uncleavable linker. 
Using this type of linkers, the bystander effect remains very limited due to the drug 
release mechanism. Moreover, due to the lysosomal degradation mechanism to 
release the cytotoxic agent, it is important to choose a payload that is active even if 
complete degradation does not occur. Despite the success, few ADCs currently under 
development use a non-cleavable linker because drug release occurs too slow and 
remains limited to antigen positive cells that internalize the full construct. However, 
uncleavable linkers remain very useful for conjugates for diagnostic purposes due to 
their high stability.  
 Acid-labile linkers rely on the difference between physiological neutral pH and the 
acidic conditions that can be found in certain cellular compartments (i.e. endosomes 
pH 5.0 – 6.5, lysosomes pH 4.5 – 5.0) and in the extracellular microenvironment of 
tumors.[101] Among others, hydrazones (Scheme 1A) are widely used as acid-labile 
sensitive linkers. This type of linker is used in two clinically approved ADCs, but 
their stability needs to be carefully analyzed in each case as it has been proven that 
sometimes are not stable in circulation.  
 Reducible linkers mostly based on disulfides are gaining importance, especially in 
the SMDC field. Glutathione (GSH), a tripeptide capable of reducing disulfide bonds, 
is essential for cell survival and its concentration is upregulated during oxidative 
stress and inflammation.[102] While the concentration of GSH is low in the 
extracellular space of healthy cells and plasma (⁓ 10 µM), 1000-fold higher 
concentrations (⁓ 10 mM) can be found in the tumor stroma and intracellular 
compartments of cancer cells. This concentration difference can be used to develop 
delivery systems based on disulfides or other reducible moieties. The main advantage 
of disulfides is that the stability and release can be easily tuned by modifying the steric 
hindrance of the adjacent carbon atoms of the disulfide. Moreover, in some cases it is 
possible to directly connect the payload and the targeting moiety (Scheme 1B). 
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However, as many payloads do not contain a free thiol, the incorporation of a self-
immolative moiety is required.  
 Enzyme sensitive linkers are widely used in both the SMDC and the ADC field. 
Their mechanism of action relies on the overexpression of certain proteases which 
can selectively cleave known sequences. The cathepsin B-cleavable dipeptide valine-
citrulline and closely related analogues (e.g. Val-Ala) are the most widely used 
enzyme sensitive linkers (Scheme 1C). Very recently, it has been shown that this type 
of linker can be processed in the absence of cathepsin B and multiple proteases are 
responsible for degradation.[103] Glycosides such as glucuronide or galactoside are 
emerging as an alternative to the traditional cathepsin B cleavable linkers. They can 
be efficiently cleaved by β-glucuronidase and β-galactosidase, respectively.[104,105]  
 
1.2.4 The payload  
Research on new anticancer drugs has been very active since the discovery of the first 
chemotherapeutic agents. After the discovery of paclitaxel and doxorubicin, it was 
believed that higher potency would improve the clinical activity because the minimum 
effective dose would be considerably reduced. Since many cytotoxic agents are derived 
from natural sources, research in natural products was largely explored. As a result, 
several highly toxic agents with different modes of actions were discovered (Figure 11). 
 
Figure 11. Molecular structures of some highly potent cytotoxic agents.  
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The new compounds can be subdivided in two main classes: DNA- and RNA- targeting 
(e.g. amanitins, pyrrolobenzodiazepines) and tubulin interacting agents (e.g. 
maytansinoids, auristatins, cryptophycins, tubulysins). Despite the higher cytotoxicity of 
these compounds compared to classical chemotherapeutics, the therapeutic window was 
not improved due to their low maximum tolerated dose. However, they present enormous 
potential to be used as cytotoxic agents in a tumor targeted delivery approach. 
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1.3 Cryptophycin  
During a screening campaign to identify new pharmaceuticals, researchers at Merck 
detected a cyclic depsipeptide with interesting properties. The compound isolated from 
cyanobacteria Nostoc sp. showed remarkable antifungal properties and was named 
cryptophycin due to its high potency against Cryptococcus sp.[106] Later on, the same 
compound (cryptophycin-1, Figure 12) was extracted from another strain of 
cyanobacteria and the total structure was proposed.[107] However, the subsequent total 
synthesis identified a wrongly assigned absolute configuration of one stereocenter, which 
was then corrected.[108] Further studies allowed the isolation of 18 new analogues from 
the same strain.[109] At about the same time, arenastatin A, better known as cryptophycin-
24 (38, Figure 12), was isolated from the marine sponge Dysidea arenaria.[110] The total 
structure of this compound was later elucidated and the first total synthesis was performed 
and improved.[111–113]  
All the discovered cryptophycins can be retrosynthetically divided in four subunits, 
namely A-D. Unit A represents the most exotic fragment being an α,β-unsaturated δ-
hydroxycarboxylic acid with four stereogenic centers and a benzylic epoxide. Fragment 
B can be derived from D-O-methyltyrosine and may contain a chlorine in the 3’-position. 
β-alanine represents the core of unit C and can be α-mono or α,α-dialkylated. Finally, L-
leucic acid constitutes the fragment D.    
 
Figure 12. Molecular structures of cryptophycin-1, cryptophycin-24, and cryptophycin-52 and retrosynthetic 
division. 
Shortly after the discovery of cryptophycin-1, biological screening assays showed a high 
cytotoxicity against several cancer cells lines, even multi-drug resistant (MDR) ones. 
These properties compromised their applicability as antifungal compounds, but motivated 
their development as anticancer drugs.[114] 
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For this reason, several structure-activity relationship (SAR) studies aiming to find a more 
active compound were started. These results will be explained more in detail in section 
1.3.2, but special attention needs to be paid to the discovery of cryptophycin-52 (32, 
LY355703).[115] This compound, identified by Eli Lilly, retained the high cytotoxicity of 
the parent compound and showed an enhanced stability towards hydrolysis, because it 
contains a dimethyl substitution at the α position of unit C, which protects the susceptible 
ester between units C and D.[116] As a result, cryptophycin-52 entered clinical trials phase 
I and II.[117–120] From the two clinical trial phase II studies, it was concluded that around 
40% of patients obtained a clinical benefit, either with partial response or disease 
stabilization. However, the activity of cryptophycin-52 was not superior to other drugs 
that were already available, and neurotoxicity was observed in some cases. The side 
effects forced a dose reduction and limited, even more, its efficacy. Consequently, further 
clinical evaluation of the compound was discontinued and opened a new era of research 
for cryptophycin.  
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1.3.1 Biological mode of action  
Tubulin is a superfamily of globular proteins composed of six different groups although 
the term tubulin usually refers to the dimers formed by the α- and β-moieties. This 
heterodimer polymerizes to form the microtubules, a major component of the eukaryotic 
cytoskeleton. They are essential in many cellular processes such as development and 
maintenance of cell shape, cell division, and mitosis. In order to fulfill their functions, 
microtubules undergo a highly dynamic process with a continuous 
polymerization/depolymerization (Figure 13).[121]   
 
Figure 13. Structure, polymerization and depolymerization dynamics of microtubules.[122] 
α- and β-tubulin are GTPases, which means that each monomer contains a guanosine 
triphosphate (GTP) molecule. However, the two GTP binding sites present different 
properties. The GTP of the α-tubulin is located in the non-exchangeable site while the 
one located at the β-tubulin is exchangeable and susceptible to hydrolysis to form 
guanosine diphosphate (GDP).  
The microtubule formation proceeds in two steps: nucleation and elongation. Shortly after 
elongation, the GTP of β-tubulin is hydrolyzed to GDP and the rate of this reaction 
determines their dynamics. Microtubules containing a GDP cap are 100 times more 
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susceptible to hydrolysis than their GTP cognates. Therefore, a GTP cap favors 
microtubule growth while shrinkage is promoted in the case that GDP is present.  
Because microtubule dynamics are crucial for cell division, disrupting them causes cell 
cycle arrest in the G2/M phase and induces apoptosis. For this reason, drugs targeting 
microtubules have emerged as good candidates for cancer treatment.[123] Depending on 
their mode of action, microtubule interacting agents can be classified in two main groups: 
microtubule stabilizers which promote the tubulin polymerization, and microtubule 
destabilizers which bind to tubulin dimers and block the formation of microtubules.[124] 
The activity of microtubule interacting agents is based on their capability to bind to 
tubulin. Up to now, five binding sites are known: vinca alkaloid domain, taxane binding 
site, colchicine region, maytansine area and laulimalide domain.  
Cryptophycin-1 (37) has high binding affinity for tubulin and inhibits its polymerization, 
hence it is a microtubule destabilizer.[125,126] The same mode of action has also been 
confirmed for other cryptophycins, such as cryptophycin-52 (32).[127,128] Interestingly, the 
exact binding mode of cryptophycin to tubulin has not yet been confirmed because no 
crystal structure of the cryptophycin-tubulin complex has been described. However, 
different experiments suggest the vinca domain as binding site of cryptophycins. First it 
was shown that binding of vinblastine is impaired upon competition with cryptophycin, 
while colchicine and paclitaxel binding are not compromised in the same experiment.[129–
131] Moreover, molecular dynamics and molecular docking studies are in agreement with 
the experimental findings.[132] Despite the high binding affinity, cryptophycins interact in 
a non-covalent manner to tubulin as they can be recovered from the tubulin complex upon 
denaturation.[133,134]  
Furthermore, the activity of cryptophycin is not reduced in MDR cells because it is a poor 
substrate for the P-glycoprotein efflux pump, a typical cell membrane protein responsible 
to transport many substances out of cells.[135] 
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1.3.2 Structure-activity relationship (SAR) studies  
Since the discovery of the first cryptophycin, several SAR studies were initiated. At first, 
the research was focused in the total synthesis and discovery of new cryptophycins with 
higher toxicity and increased stability to proteases.[136–138] As a result, cryptophycin-52 
was discovered and brought to clinical trials phase II. With the setback of its failure, SAR 
studies continued to understand the essential structural requirements for effective binding 
to tubulin to retain activity. Several analogues with high cytotoxicity have been 
discovered, but they present the same drawback than the parent compound. They lack 
tumor selectivity and thus, produce severe side effects.  
With the growing interest in tumor targeting, cryptophycins have emerged as potential 
payload.[139] Nevertheless, most of the cryptophycins lack a functional group for 
connection to a homing device. For this reason, in the last years the SAR research has 
been focused on functionalized cryptophycins that can be used for conjugation in tumor 
targeting therapy.[140] As a result, many active analogues have been discovered and 
allowed the construction of ADCs and SMDCs. The most relevant and active examples 
will be explained in the next sections.  
 
1.3.2.1 Unit A 
The unusual δ-hydroxy acid of unit A has been by far the most explored fragment of 
cryptophycin. The four consecutive stereocenters represents a challenge from the 
synthetical point of view and several strategies to obtain the desired diastereomer in short 
synthetic routes have been explored.[141–144] From early SAR studies, it was established 
that the absolute stereochemistry of the four stereocenters is of crucial importance and 
any modification results in a dramatical reduction of activity. However, certain 
modifications are tolerated in the benzylic epoxide.[145] While epoxides with other 
configurations (R/S, S/R or S/S) than the original (R/R) are much less active, the acid-
mediated opening of the β-epoxide to obtain the corresponding halohydrin retains the 
activity of the parent compound (Figure 14).[146] This can be attributed to their prodrug 
character as they are converted back to the epoxide under physiological conditions. 
Despite their higher biological activity in vitro and in vivo, the chlorohydrins never 
entered clinical trials because they cannot be formulated as stable solutions.[147] Later on, 
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it was discovered that stabilization of cryptophycin-55, the chlorohydrin of cryptophycin-
52, and other chlorohydrins is possible upon esterification of the secondary alcohol with 
glycine while retaining the high activity.[148] Esterification with other amino acids such 
as alanine or aminoisobutyric acid has also been studied, with a 50-fold and 1100-fold 
reduction of activity, respectively.   
The para position of the aromatic unit A has also been largely explored. The first studies 
aimed to increase the poor water solubility of the parent compound while retaining the 
cytotoxicity.[149–151] For this reason, different polar groups (e.g. alcohols, amines, 
carboxylic acids) have been introduced. As a result, several analogues have been obtained 
and some of them are even more potent than the parent compound. Unfortunately, many 
lost their activity against MDR cells because they became good substrates for the P-
glycoprotein transporter and thus, research was discontinued.[152] Very recently, Sanofi 
has used some of these analogues to create ADCs.   
 
Figure 14. Cytotoxicities of unit A modified cryptophycin-52 analogues (IC50 values in nM). Cell lines: KB 
and KB-3-1, human cervical carcinoma; CCRF-CEM, human T-cell leukemia; HL-60, human acute 
myelocytic leukemia; MDA-MB-231, breast carcinoma.   
 
1.3.2.2 Unit B 
The basis of the unit B is an O-methyl-D-tyrosine which, in most of the natural 
cryptophycins, is 3’-chlorinated. So far, the activity of cryptophycins has not been 
improved by modifying the unit B but certain modifications are permitted. The most 
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important feature of this unit is the absolute configuration since substitution into an O-
methyl-L-tyrosine leads to a completely inactive cryptophycin (Figure 15).[113] The 
methoxy and chloro groups are not indispensable and their absence is tolerated to a certain 
extent.[153] In this direction, a slight decrease of activity is observed for the para-hydroxy 
or para-amino substituents containing a chlorine in the meta position. More interestingly, 
the para-dimethylamino is highly tolerated and there is only a minimal reduction of 
cytotoxicity compared to the parent compound.[154]  
 
Figure 15. Cytotoxicities of unit B modified cryptophycin analogues (IC50 values in nM). Cell lines: KB and 
KB-3-1, human cervical carcinoma; CCRF-CEM, human T-cell leukemia. * Derived from cryptophycin-24. 
** Derived from cryptophycin-1. 
 
1.3.2.3 Unit C 
A β-alanine constitutes the backbone of the unit C and the replacement for natural alanine 
or other α-amino acids dramatically reduces the activity.[155] However, certain 
modifications are well tolerated, especially in the α-position. Indeed, cryptophycin-52, 
the only cryptophycin compound that was tested in clinical trials, contains an extra α-
methyl group in the unit C compared to the natural cryptophycin-1 (Figure 16). Other 
α,α-dialkylated compounds, either linear or cyclic, have been tested and their activity is 
proportionally reduced with increasing substituent size.[156] Moreover, their water 
solubility gets compromised due to their higher lipophilicity and leads to a lower 
efficiency. For this reason, more recently the incorporation of polar groups in this position 
has been reported.[157] Several groups are well tolerated and maintain the potency of the 
cryptophycin in the subnanomolar range in cervix carcinoma cells (KB-3-1). However, 
their activity is dramatically reduced in the MDR subclone (KB-V1) probably due to their 
high amphiphilicity. Interestingly, there seems to be an influence of the stereochemistry 
of the α-position, but no clear SAR correlation could be obtained.  
Chapter 1. General introduction 
48 
 
Finally, small groups can be tolerated in the β-position and, although they always lead to 
a reduced potency, it can be a good strategy to increase the amide stability between units 
B and C.  
 
Figure 16. Structure-activity relationship studies of unit C building block (IC50 values in nM). Cell lines: KB-
3-1, human cervical carcinoma; KB-V1, P-gp expressing MDR subclone of KB-3-1; CCRF-CEM, human 
T-cell leukemia; GC3, human colon carcinoma. 
 
1.3.2.4 Unit D 
The hydroxy acid of the unit D is amenable to certain modifications and even natural 
cryptophycins present several alkyl chains. Among them, the isobutyl group is the most 
commonly found and the most potent one, but the n-propyl, sec-butyl, and isopropyl 
groups retain the activity in the nanomolar range (Figure 17).[109] Moreover, the non-
natural neopentyl derivative has shown similar in vivo activity to the isobutyl residue.[158] 
Interestingly, the inversion of the chiral center does not produce a dramatical loss of 
activity in contrast to the other stereocenters.[159] More recently, the synthesis of 
functionalized cryptophycins has been reported.[160] The allyl ester cryptophycin can be 
considered as a precursor of the free carboxylic acid which can be used in targeted 
therapy. In both cases, they present high cytotoxicity with IC50 values in the low 
picomolar range against KB-3-1 cells. However, their potency is highly affected in the 
MDR subclone KB-V1 cells. While the allyl ester retains the potency in the subnanomolar 
range, the free acid shows a dramatic reduction of activity. This can be attributed to its 
higher amphiphilicity which makes it a better substrate for the P-gp efflux pump.  
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Figure 17. Structure-activity relationship studies of unit D building block (IC50 values in nM). Cell lines: KB 
and KB-3-1, human cervical carcinoma; KB-V1, P-gp expressing MDR subclone of KB-3-1; MCF-7, human 
breast adenocarcinoma. *contains a styrene moiety instead of the epoxide.  
 
1.3.3 Conjugates containing cryptophycin as payload  
The knowledge obtained from the SAR studies provided the background to create 
efficient conjugates using cryptophycin as payload for targeted therapy.[139] The 
possibility to introduce different functional groups that can be addressed with homing 
devices and the high activity against MDR cell lines makes cryptophycin a promising 
agent in this field. Although this strategy has not been largely explored, there is a growing 
interest on this class of payload as it presents features that are superior to currently used 
payloads (e.g. maytansinoids, auristatins). 
The first ADCs using cryptophycin as payload were reported from Sanofi and used the 
para position of unit A for the conjugation. The cytotoxic agent was connected to the 
antibody through the protease-sensitive dipeptide Val-Cit and did not use any self-
immolative moiety (39, Figure 18).[161] In a similar manner, Genentech used the same 
drug and linker but they incorporated the p-aminobenzyl group as self-immolative linker 
(40, Figure 18).[162] Although they obtained good in vivo and in vitro results, respectively, 
the macrocycle was unstable in mice which resulted in a considerable loss of potency. 
This instability was translated in a loss of fragments C and D leading to an inactive 
payload. Interestingly, this metabolization could not be observed in monkey, most 
probably due to the lower content of hydrolases.   
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Figure 18. First generation of ADCs featuring cryptophycin as payload. 39 was developed by Sanofi and 40 
by Genentech.  
Later on, both companies worked on raising the stability using different approaches. 
Sanofi increased the stability with two modifications in the macrocycle: (i) the 
incorporation of a methyl group in the β-position of unit C to shield the amide bond 
between units B and C and (ii) replacement of the scissile ester bond between units C and 
D by an amide. Consequently, they obtained a cryptophycin that retains the high 
cytotoxicity of the parent compound and the stability is clearly enhanced.[163] The 
conjugation of this payload to an antibody using the protease sensitive Val-Ala dipeptide 
resulted in a potent ADC that is able to eradicate tumors in nude mice bearing MDA-MB-
231 xenografts with only one dose at 5 mg/kg (41, Figure 19). Alternatively, Genentech 
modulated the payload metabolism modifying the conjugation site and the linker.[164] On 
a first attempt, they explored the conjugation of the payload to different sites of the 
antibody and reduced the enzymatic metabolism from more than 40% to 25% in an in 
vitro experiment after 24 h of incubation and thus, remarkably increased the in vivo 
efficacy. A further stability improvement was achieved employing a shorter linker which 
resulted in a highly stable conjugate in vitro and in vivo (42, Figure 19). However, no 
therapeutic efficacy has been reported for this last conjugate.  
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Figure 19. Second generation of ADCs featuring cryptophycin as payload. 41 was developed by Sanofi and 
42 by Genentech.  
The usage of cryptophycin-55 glycinate as payload in an ADC has been recently 
acknowledged in a patent (43, Figure 20).[165] In this case, the cytotoxic agent is connected 
to the HER2 targeting antibody, Trastuzumab, using a protease sensitive Val-Cit 
dipeptide as linker and a diketopiperazine forming (Pro-Gly) as self-immolative moiety. 
The cytotoxicity of the construct was evaluated in cell lines expressing different levels of 
HER2 and showed excellent specificity. However, no further details of stability or 
therapeutic activity are disclosed.  
 
Figure 20. Molecular structure of an ADC using cryptophycin-55 glycinate as payload.  
In another embodiment, the growing interest in the SMDC field has motivated the usage 
of cryptophycin in conjugation to different small molecules. Endocyte was the first to 
report a conjugate using cryptophycin-55 as payload and folic acid as targeting moiety 
(44, Figure 21).[166] The compound displayed high cytotoxicity against KB cells with an 
IC50 value in the low nanomolar range and competition experiments showed a decrease 
of cytotoxicity proving their specificity. However, no in vivo results have been reported. 
Succeeding research connected a cyclic RGD peptide to an azide unit C modified 
cryptophycin (45, Figure 21) using copper(I)-catalyzed alkyne-azide cycloaddition 
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(CuAAC).[157] The compound showed good binding affinity to integrins, which are 
overexpressed in several cancer cells. More interestingly, the incorporation of a 
carboxyfluorescein moiety between the peptide and the cytotoxic agent was used to study 
its internalization. Confocal microscopy (picture Figure 21) showed integrin mediated 
endocytosis of the compound as it ended up in the lysosomal compartment. 
 
Figure 21. SMDCs using cryptophycin as payload. The confocal microscopy study of compound 45 in WM-
115 melanoma cells is shown for (i) 15 min, (ii) 40 min, (iii) 4 h. The compound is shown in green, the 
lysosomes in red and the overlay clearly proves colocalization.  
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2. Objectives 
The main objective of this thesis was to explore the potential of cryptophycin as payload 
for targeted therapy using small molecules as delivery vehicles. Since cryptophycin 
display high cytotoxicity towards several cancer cells and is amenable to certain 
modifications to introduce functional groups, its vectorization using small molecules 
could enhance the therapeutic activity of the drug while reducing its side effects.  
The first part of this thesis (chapter 3) aimed the identification of new highly active 
cryptophycins containing different functional groups that can be used for conjugation to 
homing devices. In particular, the synthesis of cryptophycins with modifications in the 
para position of the unit B was envisioned (Figure 22). The study of their biological 
activity was planned in a cell-based cytotoxicity assay using cervix cancer cells (KB-3-
1) and, in case of active compounds, its MDR subclone (KB-V1). Moreover, the obtained 
compounds could also serve as payloads for the preparation of small molecule-drug 
conjugates (SMDCs). 
 
Figure 22. Proposed molecular structures of unit B modified cryptophycin.   
The second part (chapters 4 and 5), intended the investigation of cryptophycin-55 
glycinate as payload of SMDCs. Different peptides and peptidomimetics targeting 
receptors or enzymes such as the somatostatin receptor 2 (SSTR2) or carbonic anhydrase 
9 (CAIX) were contemplated (Figure 23). 
 
Figure 23. Schematic structure of SMDC using cryptophycin-55 glycinate as payload  
+
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In particular, an acetazolamide derivative targeting CAIX and octreotide targeting SSTR2 
were considered as ideal and validated targeting moieties to explore the capacity of 
cryptophycin-55 glycinate as payload. The conjugation between the targeting moiety and 
the drug was planned through different cleavable linkers containing spacers to increase 
their hydrophilicity. In order to proof the efficient targeting properties of the prepared 
conjugates, a series of in vitro and in vivo experiments were envisioned. 
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Abstract
Cryptophycins are naturally occurring cytotoxins with great potential for chemotherapy. Since targeted therapy provides new
perspectives for treatment of cancer, new potent analogues of cytotoxic agents containing functional groups for conjugation to
homing devices are required. We describe the design, synthesis and biological evaluation of three new unit B cryptophycin ana-
logues. The O-methyl group of the unit B D-tyrosine analogue was replaced by an O-(allyloxyethyl) moiety, an O-(hydroxyethyl)
group, or an O-(((azidoethoxy)ethoxy)ethoyxethyl) substituent. While the former two maintain cytotoxicity in the subnanomolar
range, the attachment of the triethylene glycol spacer with a terminal azide results in a complete loss of activity. Docking studies of
the novel cryptophycin analogues to β-tubulin provided a rationale for the observed cytotoxicities.
Introduction
Cryptophycins are natural occurring cyclic depsipeptides that
were first isolated from cyanobacteria Nostoc sp. ATCC 53789
in 1990 [1]. Cryptophycins target tubulin, in particular the
peptide site of the vinca domain. They block microtubule for-
mation, inhibiting their assembly and, hence, are antimitotic
agents [2,3]. Their high cytotoxicity prompted manifold studies
that were initially focussed on the total synthesis and
structure–activity relationships [4-20]. This work resulted in the
identification of cryptophycin-52, a highly biologically active
analogue of cryptophycin-1 (Figure 1).
Eli Lilly took cryptophycin-52 into clinical trials. Although
almost half of the patients obtained a benefit from the treatment,
neurotoxic side effects forced the termination of the clinical
trials [21-23]. In order to overcome the side effects of crypto-
phycin-52 and to better understand the fundamental structure
for biological activity, numerous structure–activity relationship
studies have been carried out [24-35]. However, like crypto-
phycin-52, the new analogues were not selective against cancer
cells making them not better than its parent.
In recent years the targeted delivery of cytotoxic agents has
emerged as a highly promising method to tackle selectivity
issues [36-40]. Cryptophycin-52 and many analogues lack an
addressable group to conjugate the toxin to a homing device.
For this reason, new analogues containing functional groups
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Scheme 1: Synthesis of modified unit B (13 and 14). Reagents and conditions: (a) 1) TsCl, DMAP, Et3N, CH2Cl2, rt, 4 h; 2) NaN3, DMF, 70 °C,
overnight; (b) TsCl, Et3N, CH2Cl2, rt, overnight; (c) NaI, acetone, reflux, overnight; (d) TsCl, Et3N, CH2Cl2, rt, overnight; (e) NaI, acetone, reflux,
overnight; (f) 6 or 9, K2CO3, DMF, 50 °C, overnight; (g) LiOH, H2O/MeOH/THF 1:1:1, rt, 2 h.
Figure 1: Cryptophycin-1 (1) and -52 (2).
that would allow the conjugation of a homing device were de-
veloped [41-46]. Some of these functionalized analogues have
been recently used for the preparation of antibody–drug conju-
gates (ADCs) and peptide–drug conjugates (PDCs) [46-51].
Nevertheless, there is still a strong need of novel cryptophycin
analogues with maintained activity containing a suitable func-
tional group that would allow the conjugation to the homing
device. Cryptophycin-1 contains a methoxy group in the aro-
matic ring of the unit B, which is a chlorinated derivative of
D-tyrosine. Different chains for unit B have been investigated,
albeit the elongation of the methoxy group is still unknown.
Therefore, in the current study, we embarked on the synthesis of
novel cryptophycin analogues containing different substituents
at the phenolic hydroxy group of the unit B. We intended to in-
vestigate whether the high biological activity of the parent com-
pound is retained and thus, construction of ADCs and PDCs
would be feasible. This preparation could be done using trace-
less cleavable linkers that are sensitive to the distinct physi-
ology of the tumour with enhanced level and activity of specif-
ic enzymes. The connection between the payload and the linker
is of crucial importance since its stability can dramatically
change the release and thus, the activity of the compound. For
this reason, the included functional groups were designed with
the consideration to provide appropriate stability and activity to
the future conjugate.
Results and Discussion
Design and synthesis
Previous docking studies have postulated that the methyl group
of unit B is not involved in the cryptophycin–tubulin interac-
tion [52]. Moreover, its absence did not produce a dramatic loss
of activity [24].
Based on this, we designed cryptophycin analogues modified in
the unit B. Instead of the O-methyl group that is present in the
natural cryptophycin, we attached a hydroxyethyl group or a
triethylene glycol chain terminated with an alcohol or azide, re-
spectively. These functional groups would allow the conjuga-
tion of the novel cryptophycin analogues across an appropriate
linker to an antibody or peptide. Either a virtually uncleavable
triazole (introduced by CuAAC) or scissile ester, carbonate, or
carbamate moieties were taken into account.
The synthesis of the modified unit B (Scheme 1) started with
the preparation of the two different spacers that were later
connected to the phenol. Starting from triethylene glycol (3) or
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Scheme 2: Synthesis of cryptophycin analogues 22, 23 and 24. Reagents and conditions: (a) 4-DMAP, 2,4,6-trichlorobenzoyl chloride, Et3N, THF,
0 °C, 3 h; (b) 1) piperidine, DMF, rt, 2 h; 2) 13 or 14, HOAt, EDC·HCl, Et3N, CH2Cl2, 0 °C → rt, overnight; (c) 1) TFA/CH2Cl2/H2O, rt, 2 h; 2) HATU,
HOAt, DIPEA, DMF, rt, slow addition + 2 h; (d) 1) (CH3O)3CH, PPTS, CH2Cl2, rt, 2 h; 2) AcBr, CH2Cl2, rt, 4 h; 3) K2CO3, DME/ethylene glycol
(2:1 v/v), rt, 5 min; (e) Pd(PPh3)4, phenylsilane, CH2Cl2, rt, 7 h.
2-allyloxyethanol (7) tosylations and nucleophilic displace-
ments by azide or iodide substitution provided 6 and 9 in good
yields. O-Alkylation of Boc-protected 3-chlorinated D-tyrosine
10 with 6 or 9 gave 11 and 12, again in satisfactory yields
(81–85%). Saponification of the ester moiety in 11 and 12 that
was formed concomitantly with the O-alkylation in the previous
reaction provided Boc-protected modified units B 13 and 14 in
76 and 90% yield, respectively.
The synthesis of units C–D and A succeeded as previously de-
scribed in the literature; unit A (15) and C–D (16) were
connected by Yamaguchi esterification to give 17 (Scheme 2)
[45]. Then, Fmoc was cleaved from the N-terminus of unit
C–D–A (17) using piperidine and the resulting crude amine was
coupled to the corresponding modified unit B (13 or 14),
affording the according linear cryptophycins 18 and 19 in
acceptable yields (51–59%). Compounds 18 and 19 were
treated with trifluoroacetic acid for simultaneous Boc and t-Bu
removal, which also cleaved the dioxolane ring. Subsequently,
macrolactamization was performed under pseudo-high-dilution
conditions to afford 20 and 21 as described previously [16].
Then the diol was transformed into the epoxide following a
three-step one-pot reaction as extensively used in the synthesis
of cryptophycin analogues [46]. Cryptophycin analogues 22 and
Beilstein J. Org. Chem. 2018, 14, 1281–1286.
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Table 2: Binding energies for the different cryptophycin analogues.
compd binding
energy
(kJ/mol)
max. binding
energy
(kJ/mol)
min. binding
energy
(kJ/mol)
2 36.17 36.17 17.21
22 22.61 22.61 5.44
23 32.20 32.20 10.38
24 32.70 32.70 11.72
23 were obtained in good purity after column chromatography.
The allyl ether in 23 was cleaved using Pd(PPh3)4 as Pd(0)
source and phenylsilane as scavenger to obtain the crypto-
phycin analogue 24 in good purity.
Biological evaluation
The biological activity of the modified unit B analogues was de-
termined in a cell viability assay using the human cervix carci-
noma cell line KB-3-1 (Table 1). The cryptophycin analogue 22
showed a dramatic loss of activity compared to cryptophycin-52
(2), while analogues 23 and 24 showed a reduced cytotoxicity
although their IC50 values are still in the low nanomolar range.
The observed dramatic loss of activity of analogue 22 could be
due to its poor internalization or the modification could alter the
interaction with tubulin. In order to get an extensive knowledge
of the novel analogues, we embarked in docking and modelling
studies, herein reported, and internalization studies are ongoing
in our research group.
Table 1: Cytotoxicity of cryptophycin-52 and its unit B analogues.
compd unit B IC50
KB-3-1
(nM)
2 CH2Ph(m-Cl,p-OMe) 0.015
22 CH2Ph(m-Cl,p-(OCH2CH2)3N3) 195000
23 CH2Ph(m-Cl,p-OCH2CH2OCH2CHCH2) 0.748
24 CH2Ph(m-Cl,p-OCH2CH2OH) 0.184
Docking and modelling of cryptophycin
derivatives
There is no X-ray analysis of cryptophycin–tubulin complexes
available to provide information on the binding site. Based on
biochemical evidence, binding close to the vinca-alkaloid
binding site of β-tubulin, the so called “peptide-site”, has been
proposed [2,52,53]. We performed a docking study to explain
the different affinities of the newly synthesized derivatives. The
parent compound 2 scored highest with respect to β-tubulin
binding (Table 2). Three hydrogen bonds were detected to key
residues in the peptide binding pocket of the vinca domain
(Lys176, Val177 and Tyr210). Other than previously reported
[52], the methoxy group of subunit B forms a hydrogen bond
with Lys176 (Figure 2). Another binding mode of 2 with
high binding affinity and hydrogen bond formation did not
involve any interaction of subunit B, yet it was oriented
towards the GDP binding site that might influence GTP hydro-
lysis.
Figure 2: Binding mode of 2, showing the interaction to the vinca
domain peptide binding pocket (blue). Hydrogen bonds are shown as
yellow dots with the interacting amino acid residues in magenta.
Compound 22 with the triethylene glycol-based substituent
prevents correct binding, the binding energy was decreased and
mainly nonspecific interactions outside the binding pocket were
observed (Figure 3). This was not the case for the other deriva-
tives 23 and 24 (Figure 4).
Figure 3: Docking of 22 to the vinca domain of β-tubulin. Surface and
backbone of β-tubulin are shown in blue, GDP in yellow. No hydrogen
bond formation was detected. The orientation of the azidoethoxy-
ethoxyethyl substituent prevents the inhibitor from the correct interac-
tion with the protein. The epoxide and benzyl group of subunit A are
pointing away from the binding pocket.
Besides hydrogen bond formation and binding affinity of inhibi-
tors 2, 23 and 24, π-interactions and hydrophobic contacts with
the binding pocket of the vinca domain were detected
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Figure 4: Docking of 24 to β-tubulin. Surface and backbone of
β-tubulin are shown in blue, GDP in yellow. H-bonding (yellow dots)
was detected with Lys176 and Asp179 in magenta. The benzyl group
and the epoxide of subunit A are directed towards the peptide binding
pocket, while the hydroxyethyl group is positioned towards the GDP
binding pocket forming an H-bond with Asp179.
that would in turn increase the affinity of the inhibitor and
its effect on the protein (Supporting Information File 1,
Table S1).
Conclusion
In summary, three new cryptophycin analogues with a modi-
fied unit B have been designed and successfully synthesized.
The novel analogues were less active than cryptophycin-52 in
the KB-3-1 cell line. Analogue 22 showed a dramatic loss of ac-
tivity whereas analogues 23 and 24 showed a reduced activity
but were still very cytotoxic.
Supporting Information
Supporting Information File 1
Experimental part and analytical data.
[https://www.beilstein-journals.org/bjoc/content/
supplementary/1860-5397-14-109-S1.pdf]
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ABSTRACT: Traditional chemotherapeutics used in cancer
therapy do not preferentially accumulate in tumor tissues. The
conjugation to delivery vehicles like antibodies or small
molecules has been proposed as a strategy to increase the
tumor uptake and improve the therapeutic window of these
drugs. Here, we report the synthesis and the biological
evaluation of a novel small molecule−drug conjugate
(SMDC) comprising a high-aﬃnity bidentate acetazolamide
derivative, targeting carbonic anhydrase IX (CAIX), and
cryptophycin, a potent microtubule destabilizer. The bio-
logical activity of the novel SMDC was evaluated in vitro,
measuring binding to the CAIX antigen by surface plasmon
resonance and cytotoxicity against SKRC-52 cells. In vivo
studies showed a delayed growth of tumors in nude mice bearing SKRC-52 renal cell carcinomas.
1. INTRODUCTION
Most cytotoxic compounds, which are used for cancer
chemotherapy, do not accumulate selectively at the site of
the disease.1,2 The suboptimal biodistribution properties of
these drugs limit clinical eﬃcacy and may cause severe side
eﬀects.3 Antibodies and small molecules that are able to bind
accessible tumor-associated antigens have been proposed as
carriers to deliver cytotoxic payloads to the tumor site. The
corresponding products are called antibody−drug conjugates
(ADCs) and small molecule−drug conjugates (SMDCs),
respectively.4 Four ADCs (Kadcyla, Adcetris, Besponsa, and
Mylotarg) have been approved for cancer treatment.5
The prolonged circulatory half-life of ADC products can
induce side eﬀects as a result of premature release of the
payload. In addition, challenges related to the preparation of
ADCs with homogenous drug−antibody ratio, as well as high
manufacturing cost, may hinder ADC development.6 SMDC
products may represent an alternative to ADCs.7 Their small
size facilitates rapid and uniform diﬀusion into tissues,8
potentially reaching high tumor/organ ratios at earlier time
points. Lower cost-of-goods,9 lack of immunogenicity,10
amenability to chemical synthesis, and easier analytical
characterization may represent opportunities for SMDC
development compared to ADCs. Promising results from
nuclear medicine studies and preclinical experiments have been
obtained with certain ligands of folate receptors,11 prostate-
speciﬁc membrane antigen,12 somatostatin receptors,13 and
carbonic anhydrase IX (CAIX),3,7,14 indicating that it is
possible to target diﬀerent types of tumors with small organic
compounds.
Carbonic anhydrase IX (CAIX) is a transmembrane protein
virtually absent in most of the healthy human tissues, with the
exception of certain gastrointestinal structures.15,16 CAIX
represents an ideal target for SMDC development since its
expression is enhanced in tumor hypoxia and certain cancer
types. A growing body of evidence indicates that binding of
antibodies or small ligands to CAIX does not induce receptor
internalization.3,17−22 We have recently reported the discovery
of a noninternalizing acetazolamide derivative from a DNA-
encoded library and its use as a delivery vehicle for tumor
targeting.7,23 An SMDC product based on this ligand, called
AAZ+, showed a comparable in vivo activity to an ADC
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targeting the same antigen.7 Moreover, we could show that the
anticancer activity of the SMDC can be enhanced by the
combination of immune-oncology drugs like antibody−
cytokine fusion proteins.14
Not only the ligands but also the linker−payload
combination is signiﬁcant for the development of eﬃcacious
targeted cytotoxic products.24,25 In fact, the failure of early
ADCs and SMDCs was partially due to the insuﬃcient potency
of the chosen payloads. The importance of using more potent
cytotoxic agents has been recognized, prompting research in
the identiﬁcation of highly active drugs. Indeed, since the
tumor-targeting performance of AAZ and AAZ+ decreases at
doses above 250 nmol/kg, our groups have searched for
cytotoxic payloads, which could potentially outperform
conventional drugs used in ADC and SMDC research.
Cryptophycins (Figure 1) are cyclic depsipeptides with a
bacterial origin, which show promise as payloads to be used in
targeted therapy.26 Cryptophycins display a very high
cytotoxicity (typically in the low picomolar range) on a
broad variety of cancer cells, including multidrug-resistant
ones.27 Initial studies focused on the total synthesis and
application of cryptophycins as traditional chemotherapeutics,
but disappointing results in monotherapy phase II clinical trials
prompted a focus shift toward ligand-based pharmacodelivery
approaches.28,29 However, the parental compound lacks an
addressable functional group for the conjugation to a homing
device. Therefore, research has been focused on the generation
of cryptophycin derivatives that can be conjugated and
subsequently released, preserving the potent cytotoxicity of
the parent compound.30−33
The para position of the aromatic ring of unit A has proven
to be a suitable position to be modiﬁed, and ADCs using this
anchoring point have been produced.34−37 Another position
that can be modiﬁed is the epoxide of unit A. Although this site
plays an essential role for the high cytotoxicity, it tolerates
certain modiﬁcations. Cytotoxicity is retained upon epoxide
opening with HCl to give a chlorohydrin, presumably due to
the epoxide-forming reverse reaction under physiological
conditions. Hence, the secondary alcohol of the chlorohydrin
permits conjugation to the homing device, since esteriﬁcation
is an elegant way to stabilize the compound while retaining the
cytotoxicity.38
2. RESULTS AND DISCUSSION
The use of cryptophycin payloads has been studied for the
preparation of ADCs, but in vivo applications of cryptophy-
cin−SMDC have not yet been reported. For this reason, we
embarked on a project aiming at the synthesis and biological
evaluation of a conjugate bearing a bidentate acetazolamide
ligand, cleavable Val-Cit dipeptide with para-aminobenzyl self-
immolative part, and cryptophycin-55 glycinate as a payload,
and studied its biological eﬀect. Cryptophycin-55 glycinate (3)
was prepared as previously described with slight modiﬁca-
tions.38 The cleavable linker 4 was prepared starting from
Fmoc-Val-Cit-PAB; the Fmoc group was removed and a
triethylene glycol spacer containing a maleimide moiety was
Figure 1. Structures of cryptophycin-52 (1), cryptophycin-55 (2), and cryptophycin-55 glycinate (3).
Scheme 1. Synthesis of an Acetazolamide−Cryptophycin Conjugatea
aReagents and conditions: (a) N,N-diisopropylethylamine (DIPEA), dimethylformamide (DMF), room temperature (RT), 3 h; (b) Tris buﬀered
saline (TBS), DMF, RT, o.n.
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coupled to increase the solubility of the conjugate and allow
the conjugation to the acetazolamide moiety via Michael
addition. Then, the alcohol of the para-aminobenzyl moiety
was activated with bis(4-nitrophenyl) carbonate and the linker
4 was obtained in good yield and purity. Next, linker 4 was
coupled to cryptophycin-55 glycinate (3) via carbamate linkage
obtaining 5 with satisfactory yield (73%) and purity (Scheme
1). Conjugation of 5 to the acetazolamide ligand 6 yielded the
ﬁnal conjugate 7 (48%) in excellent purity.
The aﬃnity of the novel SMDC (7) to recombinant human
CAIX was determined using surface plasmon resonance (SPR)
(Figure 2). Conjugate 7 was bound in a concentration-
dependent manner to immobilized CAIX in agreement with
previous data obtained using similar derivatives of AAZ+ (i.e.,
we could calculate an apparent binding constant of 3.4 nM for
AAZ+-ValCit-Cry55gly, similar to the KD value previously
reported for AAZ+-ValCit-MMAE).7,14
An in vitro cytotoxicity cell-based assay was performed using
the cell line SKRC-52 (Figure 3). The unmodiﬁed payload 3
showed a cytotoxicity in the low nanomolar range (IC50 = 7.9
nM). Indeed, cryptophycin-55 glycinate was remarkably less
potent than expected when compared to other cell lines.39
Monomethyl auristatin E (MMAE) using the same cell line
and protocol showed a IC50 of 1.5 nM.
24 As expected,
conjugate 7 showed a decreased cytotoxicity compared to the
unmodiﬁed drug, proving the prodrug behavior characteristic
of noninternalizing conjugates.
The antitumor activity of compound 7 was investigated in
vivo in nude mice bearing subcutaneous SKRC-52 renal cell
carcinomas (Figure 4). An optimal and safe dose correspond-
ing to 250 nmol/kg was determined on the basis of dose-
escalation studies in nude mice (Supporting Information
Figure S5) and previously published biodistribution studies.24
Mice treated with compound 7 enjoyed a therapeutic beneﬁt
with a slower tumor growth, especially during the treatment (p
= 0.05 at day 14), compared with the control group (saline). In
comparison to the lead compound featuring MMAE as the
payload administered at the same dose, the therapeutic activity
was signiﬁcantly inferior. Under these experimental conditions,
neither acute toxicity nor signiﬁcant loss of weight could be
observed for mice treated with the compounds bearing either
cryptophycin or MMAE as the payload.
3. CONCLUSIONS
In summary, we have generated a novel cryptophycin−
acetazolamide conjugate targeting CAIX. The SMDC product
showed excellent aﬃnity to the target and a noninternalizing
behavior in an in vitro cytotoxicity assay. The compound
exhibited a moderate antitumor eﬀect in vivo, which was,
however, inferior to that of an analogous compound based on
MMAE as the payload. The lower therapeutic activity observed
with the cryptophycin-55 glycinate, compared to that of the
MMAE conjugate, correlates with the lower in vitro potency of
the corresponding free drugs and provides a motivation to
search for more potent cryptophycin derivatives.
4. EXPERIMENTAL SECTION
4.1. General. The general information about the used
materials and methods, NMR, and high-performance liquid
chromatography (HPLC) spectra can be found in the
Supporting Information.
4.2. Syntheses. 4.2.1. Cryptophycin-55 Glycinate (3).
Cryptophycin-55 was prepared as previously reported.32
Slightly modiﬁed protocol from Liang et al. was used to
synthesize cryptophycin-55 glycinate.38 Cryptophycin-55 (62
mg, 88 μmol, 1 equiv), DCC (27.2 mg, 132 μmol, 1.5 equiv),
Boc-glycine (23.1 mg, 132 μmol, 1.5 equiv), and 4-DMAP
(1.07 mg, 8.8 μmol, 0.1 equiv) were placed under argon
atmosphere and dissolved in 1 mL of dry dichloromethane
(DCM). The solution was stirred for 2 h 30 min at RT. Then,
2 mL of EtOAc/PE 3:1 was added and the solution was stirred
for 10 min. The solution was ﬁltered through Celite, washed
with EtOAc/PE 3:1 (100 mL), and the solvent was removed
under reduced pressure. The crude was dissolved in 4 mL of
dry DCM, 120 μL of 4 M HCl in dioxane was added, and the
solution was stirred overnight at RT. Then, the solvent was
removed under reduced pressure and the residue was puriﬁed
by reversed-phase (RP)-HPLC (method P1) to yield
cryptophycin-55 glycinate triﬂuoroacetate salt (63.4 mg, 82%
yield) as a white powder after freeze-drying. 1H NMR (600
MHz, CDCl3): δ (ppm) = 0.94 (d, J = 6.5 Hz, 3H, uD-C
δH3),
0.99 (d, J = 6.5 Hz, 3H, uD-CδH3), 1.00 (d, J = 7.2 Hz, 3H,
uA-CεHCH3), 1.08 (s, 3H, uC-C(CH3)2), 1.18 (s, 3H, uC-
C(CH3)2), 1.63−1.68 (m, 1H, uD-CβHA), 1.73−1.79 (m, 1H,
uD-CγH), 1.90−1.95 (m, 1H, uD-CβHB), 2.17−2.23 (m, 1H,
uA-CγHA), 2.54−2.57 (m, 1H, uA-CγHB), 2.64−2.69 (m, 1H,
uA-CεH), 2.94 (dd, J = 14.5, 8.5 Hz, 1H, uB-CβHA), 3.07−3.14
(m, 3H, Gly-HA, uB-CβHB, uC-CβHA), 3.34−3.41 (m, uC-
CβHB), 3.67 (d, J = 16.6 Hz, 1H, Gly-HB), 3.88 (s, 3H, uB-
OCH3), 4.56 (td, J = 7.8, 5.1 Hz, uB-C
αH), 4.73 (t, J = 10.6
Hz, 1H, uA-CδH), 4.81 (d, J = 10.2 Hz, 1H, uA-CηH), 4.93
(dd, J = 10.9, 2.7 Hz, 1H, uD-CαH), 5.42 (d, J = 10.2 Hz, 1H,
uA-CζH), 5.74 (dd, J = 15.4, 1.8 Hz, 1H, uA-CαH), 6.27 (br,
1H, uB-NH), 6.52 (ddd, J = 15.2, 11.0, 4.2 Hz, 1H, uA-CβH),
Figure 2. SPR analysis: binding of acetazolamide−cryptophycin
conjugate 5 to immobilized CAIX.
Figure 3. In vitro toxicity of cryptophycin-55 glycinate (unconjugated
drug) and compound 7 on the SKRC-52 tumor cells.
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6.86 (d, J = 8.4 Hz, 1H, uB-C5′H), 7.05 (dd, J = 8.4, 2.2 Hz,
1H, uB-C6′H), 7.19 (d, J = 2.2 Hz, 1H, uB-C2′H), 7.27−7.37
(m, 5H, uA-CarH).
4.2.2. Maleimide-PEG4-Val-Cit-PAB-PNP (4). Fmoc-Val-Cit-
PABOH (500 mg, 0.83 mmol) was dissolved in N-methyl
pyrrolidone (10 mL), diethylamine (2 mL) was added, and the
solution was stirred overnight at room temperature. Then, the
solvent was removed under high vacuum and the obtained oil
was resuspended in DCM. The suspension was placed in an
ultrasonic bath for 10 min; the solid was ﬁltered oﬀ, washed
with DCM, and dried in high vacuum to yield H-Val-Cit-
PABOH as a beige solid (260 mg, 82% yield).
Maleimide-PEG4-OH (190 mg, 0.55 mmol, 1.2 equiv) and
DIPEA (321 μL, 1.85 mmol, 4 equiv) were premixed in DMF
(6.5 mL) and added to H-Val-Cit-PAB (175 mg, 0.46 mmol, 1
equiv). HATU (209 mg, 0.55 mmol, 1.2 equiv) and HOAt (75
mg, 0.55 mmol, 1.2 equiv) were dissolved in DMF (6.5 mL)
and added to the reaction mixture. The solution was stirred at
room temperature for 2 h, and then, the solvent was removed
under reduced pressure. The product was taken up in MeOH,
the solution ﬁltered oﬀ, and the ﬁltrate puriﬁed by column
chromatography using DCM/MeOH (8:2) as an eluent to
provide Maleimide-PEG4-Val-Cit-PABOH as a yellow oil (215
mg, 66% yield).
Maleimide-PEG4-Val-Cit-PABOH (120 mg, 0.17 mmol, 1
equiv) was dissolved in anhydrous DMF (1.5 mL), and bis(4-
nitrophenyl) carbonate (103 mg, 0.34 mmol, 2 equiv) and
DIPEA (45 μL, 0.26 mmol, 1.5 equiv) were added. The
solution was stirred at room temperature for 3 h, and then, the
solvents were removed under reduced pressure. The product
was puriﬁed by column chromatography using DCM/MeOH
(9:1) as an eluent to obtain 2 as a slightly yellowish solid (95
mg, 64% yield). LC−MS (method A): tr = 8.61 min, 92%
purity (λ = 220 nm). m/z calcd for [C40H54N7O15]
+: 872.37
[M + H]+; found: 872.36.
4.2.3. Maleimide-PEG4-Val-Cit-PABC-Cry55-gly (5). 3 (8.7
mg, 9.94 μmol, 1 equiv) and 4 (9.5 mg, 10.90 μmol, 1.1 equiv)
were dissolved in DMF (0.5 mL), DIPEA (5.2 μL, 29.82 μmol,
3 equiv) was added, and the solution was stirred at room
temperature for 3 h. Then, it was directly puriﬁed by RP-
HPLC (method P1); fractions containing the desired product
were freeze-dried to aﬀord 5 as a white powder (10.9 mg, 73%
yield). LC−MS (method A): tr = 10.52 min, >99% purity (λ =
220 nm), m/z calcd for [C72H99Cl2N9O21]
2+: 747.82 [M
+2H]2+; found: 747.82.
4.2.4. AAZ+ (6). Compound 6 was synthesized as previously
reported.7
4.2.5. AAZ+-ValCit-Cry55gly (7). Compound 6 (3.6 mg,
2.51 μmol, 2.5 equiv) was dissolved in 500 μL of degassed TBS
(pH 7.4). Compound 5 (1.5 mg, 1.00 μmol, 1.0 equiv) was
added as a DMF solution (500 μL), and the reaction mixture
was stirred at room temperature overnight. The crude mixture
was diluted in 500 μL of H2O and 500 μL of CH3CN, and
puriﬁed by RP-HPLC (method P2). Product-containing
fractions were identiﬁed by high-resolution mass spectrometry
and lyophilized overnight to aﬀord 7 (AAZ+-ValCit-Cry55gly;
1.4 mg, 48% yield). LC−MS (method B): tr = 3.51 min, >99%
purity (λ = 260 nm), m/z calcd for [C128H174Cl2N26O43S3]
2+:
1464.5378 [M + 2H]2+; found: 1464.5367; m/z calcd for
[C128H175Cl2N26O43S3]
3+: 976.6943 [M + 3H]3+; found:
976.6956
4.3. Surface Plasmon Resonance. Surface plasmon
resonance (SPR) experiments were performed at room
temperature using a Biacore S200 instrument (GE Health-
care). CM5 chips (Series S) and ﬁltered phosphate-buﬀered
saline (PBS) pH 7.4 with dimethyl sulfoxide (DMSO) (5% v/
v) as a ﬂow buﬀer were used for all experiments. Human CAIX
was immobilized on the chip to 500 response units (R.U.)
using EDC·HCl and NHS according to the manufacturer’s
instructions. Serial dilutions of compound 7 (AAZ+-ValCit-
Cry55gly) in a running buﬀer at a ﬂow rate of 20 μL/min were
used as analytes. The chip surface was regenerated after each
cycle by a short treatment with DMSO (50% v/v) in PBS.
Sensorgrams were solvent-corrected and the binding kinetics
was analyzed with the Biacore S200 evaluation software using
the 1:1 Langmuir binding model.
4.4. Cell Culture and In Vitro Cytotoxicity Assay. The
human renal cell carcinoma cell line SKRC-52 was kindly
provided by Professor E. Oosterwijk (Radboud University
Nijmegen Medical Centre, Nijmegen, The Netherlands). Upon
thawing, cells were maintained in culture-full growth medium
(Roswell Park Memorial Institute (RPMI) added with 10%
fetal calf serum (FCS) and 1% antibiotic−antimycotic;
Invitrogen) at 37 °C and 5% CO2. When reaching 90%
conﬂuence, cells were detached using trypsin−ethylenediami-
netetraacetic acid (EDTA) 0.05% (Invitrogen) and re-seeded
at a dilution of 1:6.
Figure 4. Therapy experiment of conjugates 7 and 8 (250 nmol/kg). (A) Tumor volume changes for diﬀerent treatment groups. (B) Animal body
weight changes during the in vivo eﬃcacy study. Intravenous administration of the corresponding compound is indicated by the arrows.
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SKRC-52 cells were seeded in 96-well plates in RPMI added
with 10% FCS (100 μL) at a density of 5 × 103 cells/well. The
medium was replaced after 24 h with fresh medium containing
diﬀerent concentrations of test substance (starting concen-
tration of 100 nM, 1:2 dilution steps), and plates were
incubated under standard culture conditions. After 72 h, the
medium was removed, MTS cell viability dye (20 μL,
Promega) was added in 150 μL of fresh medium, the plates
were incubated for 2 h under standard culture conditions, and
the absorbance at 490 nm was measured on a Spectra Max
Paradigm multimode plate reader (Molecular Devices; back-
ground correction was performed by measuring the absorbance
at 630 nm). Experiments were performed in triplicates, and the
average cell viability was calculated as measured background-
corrected absorbance divided by the absorbance of untreated
control wells. IC50 values were determined by ﬁtting data to
the four-parameter logistic equation, using Prism 7 software
(GraphPad Software) for data analysis.
4.5. Animal Studies. The animal studies were performed
in accordance with Swiss animal welfare laws and regulations
(license number 27/2015, granted by Veterina ̈ramt des
Kantons Zürich).
4.5.1. Tumor Implantation. SKRC-52 cells were grown as
described above to 80% conﬂuence and detached with
trypsin−EDTA 0.05% (Life Technologies). Cells were rinsed
once with Hank’s balanced salt solution (HBSS, pH 7.4), and
counted and suspended again in HBSS to give a ﬁnal
concentration of 3.4 × 107 cells/mL. Aliquots of 5 × 106
cells (150 μL of the suspension) were injected subcutaneously
into the right ﬂank of athymic BALB/c nu/nu mice (8−10
weeks old females, Janvier).
4.5.2. Dose Escalation. Athymic BALB/c nu/nu mice
(females, 8−10 weeks old, no tumors, Janvier) were injected
intravenously with diﬀerent doses of compound 7 (AAZ+-
ValCit-Cry55gly; 10, 25, 125, 250, and 500 nmol/kg; n = 1 per
group) ﬁve times, once every two days (starting from day 1;
Figure S5). None of the doses tested resulted in a signiﬁcant
acute body weight loss.
4.5.3. Therapy Experiment. Tumors were allowed to grow
to an average volume of 75 mm3. Three groups (5 mice each)
were formed randomly. The treatment was started by
intravenously injecting a solution of AAZ+-ValCit-Cry55gly
(compound 7), AAZ+-ValCit-MMAE (compound 8), or
vehicle (PBS containing 1% of DMSO) (lateral tail vein) at
250 nmol/kg. All compounds were prepared and injected as
solutions in sterile PBS containing 1% DMSO. The mice were
weighed, and the tumor sizes were monitored daily with an
electronic caliper. Tumor volume calculation was done by
multiplying (long side) × (short side) × (short side) × 0.5.
Once the termination criteria were reached, the animals were
sacriﬁced. GraphPad Prism 7 was used for data analysis
(regular two-way ANOVA followed by Bonferroni test).
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ABSTRACT: Tumor targeting has emerged as an advantageous approach to improve the efficacy and safety of cytotoxic agents or 
radiolabeled ligands that do not preferentially accumulate in the tumor tissue. The somatostatin receptors (SSTRs) belong to the G-
protein-coupled receptor superfamily and are overexpressed in many neuroendocrine tumors (NETs). SSTRs can be efficiently tar-
geted with octreotide, a cyclic octapeptide derived from native somatostatin. The conjugation of cargoes to octreotide represents an 
attractive approach for effective tumor targeting. In this study, we conjugated octreotide to cryptophycin, a highly cytotoxic dep-
sipeptide, through the protease cleavable Val-Cit dipeptide linker using two different self-immolative moieties. The biological ac-
tivity was investigated in vitro and the stability of the conjugates was largely influenced by the self-immolative part. Replacement 
of cryptophycin by the infrared cyanine dye Cy5.5 was exploited to elucidate the tumor targeting properties of the conjugates in 
vitro and in vivo. The compound efficiently and selectively internalized in cells overexpressing SSTR2 and accumulated in xeno-
grafts for prolonged time. Our results on the in vivo properties indicate that octreotide may serve as an efficient delivery vehicle for 
tumor targeting.   
INTRODUCTION 
Cancer therapy has experienced several paradigm changes 
during the last decade from small molecule drugs over target-
ed therapy with antibody-drug conjugates (ADCs) to ap-
proaches in immuno-oncology. Originally tumor therapy was 
based on cytotoxic drugs as mono or combination therapy 
(alkylating agents like cisplatin, chlorambucil, procarbazine, 
carmustine; antimetabolites like methotrexate, cytarabine, 
gemcitabine; microtubule-binding agents like vinblastine, 
paclitaxel, or topoisomerase inhibitors). Traditional chemo-
therapeutics (e.g. paclitaxel, doxorubicin) usually do not pref-
erentially accumulate in tumors but affect all tissues, which 
leads to detrimental side effects.1 Thus, targeted therapy with 
antibody-drug conjugates (ADCs) and, more recently, with 
small molecule-drug conjugates (SMDCs), has emerged as a 
viable alternative to enlarge the therapeutic window.2–6 With 
the approvals of Adcetris® (Seattle Genetics/Millennium), 
Kadcyla® (Genentech/Roche), Besponsa® (Wyeth/Pfizer), the 
re-approval of Mylotarg® (Wyeth/Pfizer) and more than 80 
ADCs in clinical trial pipelines, ADCs are to be considered a 
new class of pharmaceuticals. Compared to classical cytotoxic 
drugs, ADCs have the benefit of higher specificity towards 
tumor cells and controllable release mechanisms at the site of 
action. Small molecule-mediated targeting represents ad-
vantages in terms of the straightforward organic synthesis of 
SMDCs and their uniform structure compared to antibodies. 
Indeed, small molecule ligands have been used to efficiently 
target tumors expressing the folate receptor,7 prostate-specific 
membrane antigen (PSMA),8 carbonic anhydrase IX (CAIX),9–
11 and somatostatin receptors (SSTRs).12 
The somatostatin receptors (SSTRs) belong to the G-
protein-coupled receptor family and can be subdivided into 
five different subtypes (SSTR1-SSTR5). Many neuroendo-
crine tumors (NETs) overexpress the somatostatin receptor 
genes, especially SSTR2, followed by SSTR1 and SSTR5.13 
Octreotide is a short synthetic octapeptide derived from the 
natural somatostatin with high affinity and selectivity for 
SSTR2. Moreover, it has a better metabolic stability and half-
life than somatostatin due to the incorporation of D-amino 
acids and a disulfide bridge.14 As a result, octreotide has been 
used to specifically deliver a large number of cytotoxic agents 
such as paclitaxel,15 doxorubicin,16 periplocymarin17 or perip-
logenin.18 Moreover, octreotide is routinely used in clinical 
practice for tumor diagnostic imaging (e.g. OctreoScan, 68Ga-
DOTATATE).19,20 
In this regard, the usage of potent cytotoxic agents is an at-
tractive approach to increase the efficacy and reduce the dos-
age. Hence, cryptophycins, potent microtubule destabilizers, 
represent promising agents to be conjugated to octreotide for 
tumor targeting.21  
  
Cryptophycins are naturally occurring cyclic depsipeptides 
that were first isolated from cyanobacteria.22 They target tubu-
lin and block the microtubule formation leading to high cyto-
toxicity against many cancer cell lines. Moreover, they are a 
weak substrate for the P-gp efflux pump and, consequently, 
the cytotoxicity is only slightly reduced in multidrug-resistant 
(MDR) cancer cells.23 Due to these characteristics, several 
cryptophycin analogues were investigated as chemotherapeu-
tics, and cryptophycin-52 (LY-355703) was brought to the 
clinics by Eli Lilly. However, the clinical development was 
discontinued during phase II because of side effects and insuf-
ficient efficacy.24,25 Subsequent research focused on several 
structure-activity relationship studies.26–30 Special emphasis 
was put on the introduction of a functional group enabling 
conjugation to a homing device for targeted tumor therapy.31–
37  
Sanofi and Genentech developed cryptophycin derivatives 
as payloads in the ADC field.38–40 In particular, cryptophycin 
modified in the para position of the phenyl ring in unit A has 
been used in this context, but has shown to be highly unstable 
in murine plasma, which made the use of these conjugates 
impossible for preclinical development of new ADCs. Stabil-
ity problems of the macrocycle could subsequently be over-
come by applying modifications in the payload41 or changing 
the anchoring point to the antibody.42 In strong contrast, very 
little is known about small molecules conjugated to crypto-
phycin as delivery agents.43  
We have recently communicated the application of acetazo-
lamide as a homing device to deliver cryptophycin-55 
glycinate to tumors overexpressing carbonic anhydrase IX. 
This is the first report showing in vivo data of a SMDC com-
prising cryptophycin.44 Here we describe the employment of 
cryptophycin-55 glycinate as potent payload to be released in 
tumors overexpressing SSTR2 using octreotide as delivery 
vehicle. These findings demonstrate that efficient tumor deliv-
ery can be achieved with small molecules such as octreotide 
and that cryptophycin is a valid payload for targeted tumor 
therapy. 
RESULTS AND DISCUSION 
Design and Synthesis of octreotide-cryptophycin conju-
gates 
Cryptophycin-55 glycinate was selected as the payload and 
octreotide as the targeting moiety to develop cryptophycin 
conjugates targeting SSTR2. The payload was connected to 
the C-terminus of the cathepsin B-cleavable dipeptide se-
quence Val-Cit across two different self-immolative dipep-
tides (Gly-Pro or Pro-Gly) designed to form a diketopipera-
zine.45 The N-terminus contained an azide moiety for subse-
quent copper(I)-catalyzed alkyne-azide cycloaddition (Cu-
AAC) to an alkyne functionalized octreotide.  
The conjugate synthesis started with the preparation of the 
linkers (1 and 2) using solid-phase peptide synthesis (SPPS), 
followed by coupling to cryptophycin-55 glycinate (3) across 
an amide bond (Scheme 1) to obtain compounds 4 and 5 in 
excellent purities and good yields (54-79%). The final CuAAC 
reaction of compounds 4 and 5 with alkyne functionalized 
octreotide 6 resulted to the conjugates 7 and 8. 
Binding affinity 
The binding affinity of the conjugates was evaluated in vitro 
using a radioligand binding competition assay with human 
SSTR2 and was compared to octreotide. Conjugates 7 and 8 
displayed a low nanomolar IC50 affinities (0.62 nM and 1.3 
nM, respectively) comparable to the value of the free ligand 
octreotide (0.5 nM) (Figure 1A). 
 
Scheme 1. Synthesis of octreotide-cryptophycin conjugates 7 and 8 
Reagents and conditions: a) 1 or 2 (2 eq), PyBOP (2 eq), HOBtꞏH2O (2.25 eq), DIPEA (2.5 eq), DMF, RT, 4 h; b) CuSO4ꞏ5H2O (0.6 eq), 
sodium ascorbate (0.4 eq), DMF/H2O (1:1), 40 ºC, 24 h. 
  
 
Figure 1. (A) Binding affinity towards SSTR2 of free ligand (oc-
treotide), conjugates 7, 8, and 10. (B) in vitro cytotoxicity of the 
compounds 3, 7, and 8 and metabolite Gly-Pro-Cry-55gly in the 
AtT20 cell line. (C) Plasma stability of conjugates 7 and 8 in mu-
rine and human plasma. 
In vitro cytotoxicity 
AtT20 murine pituitary cancer cells were incubated with in-
creasing concentrations of compounds 7 and 8 to determine 
their cytotoxicity, which was compared to free payload 3 
(Figure 1B). Cryptophycin-55 glycinate showed high potency 
with an IC50 in the low nanomolar range (3.53 nM). Unexpect-
edly, the activity of conjugates 7 and 8 was remarkably differ-
ent. While conjugate 8 maintained the high cytotoxicity (IC50 
of 8.37 nM), compound 7 showed a reduced cytotoxicity (IC50 
= 51.23 nM), albeit still in the nanomolar range. 
Plasma stability 
The stability of conjugates 7 and 8 was evaluated in vitro at 
37 ºC in murine and human plasma. The stability was dramati-
cally influenced by the self-immolative moiety (Figure 1C). 
Compound 7 exhibited poor stability in mouse plasma (t1/2 = 
30 min) and moderate stability in human plasma (t1/2 = 23 h). 
Conversely, conjugate 8 was remarkably stable in mouse 
plasma (t1/2 > 24 h) and also slightly more stable in human 
plasma compared to compound 7 (t1/2 = 24 h). The sufficient 
stability of compound 8 compared to the circulatory half-life 
(104 min, Figure 2B) close to that measured for octreotide 
acetate in humans justified the further investigation of its bio-
logical activity. 
Receptor and conjugate internalization 
In the absence of somatostatin, SSTR2 localizes primarily at 
the plasma membrane and is known to be rapidly internalized 
upon ligand binding. However, the rate and extent of internali-
zation can vary widely depending on the agonist and its bind-
ing affinity.46 When evaluating the ability to induce internali-
zation of the receptor in a SSTR2-positive cell model both 
conjugates induced internalization of SSTR2, which localized 
to the trans-Golgi network/late endosomal compartment (Fig-
ure 2A).47 To investigate the tumor homing properties of oc-
treotide conjugates in vivo and to confirm that they internal-
ized into the cells, the more stable conjugate 8 was selected 
and the cytotoxic moiety was replaced by the infrared dye 
Cy5.5 for the visualization of the conjugate. The dye was cou-
pled to the spacer 2 across an amide bond (Scheme S1) to 
obtain the intermediate 9 that was then “clicked” to 6 using 
CuAAc to obtain the fluorescently labeled conjugate 10 with 
satisfactory yield and excellent purity. We obtained low na-
nomolar IC50 when the affinity of compound 10 towards 
SSTR2 was measured using radioligand displacement. This 
confirmed that introduction of the fluorescent dye did not alter 
the affinity compared to the free ligand (Figure 1A). SSTR2 
expressing AtT20 cells showed effective internalization of the 
construct after only 10 min in live cell confocal microscopy 
analyses. In addition, high concentration of the conjugate 
could be detected at the perinuclear space, similar to the recep-
tor itself, upon 30 min of incubation (Figure S1). The internal-
ization could be efficiently competed with a 100-fold excess 
of the free ligand confirming internalization by the receptor 
mediated endocytosis. Moreover, no internalization was ob-
served in A549 cells that express low levels of SSTR2. 
In vivo tumor imaging 
The tumor-targeting ability of conjugate 10 was evaluated 
in mice bearing AtT20 xenografts that express high levels of 
SSTR2. Compound 10 was administered intravenously at 1 
mg/kg and whole-body imaging at different time points was 
performed (Figure 2C). A high percentage of the conjugate 
could be detected in liver and kidneys at early time points, 
correspondent to the clearance pattern of radiolabeled oc-
treotide derivatives.48 However, preferential accumulation of 
the compound 10 in the tumor over the healthy tissues not 
involved in the compound excretion could be observed and the 
conjugate showed good homing properties with detection in 
the tumor up to 7 days. 
  
 
Figure 2. (A) Concentration-dependent internalization of SSTR2 in AtT20 cells. Cells were treated for 30 min at 37 °C with 10 or 1000 
nM of octreotide and corresponding octreotide-cryptophycin conjugates 7 and 8. (B) Pharmacokinetic profile of conjugates 8 and 10 in 
heterozygous NCR mice. (C) In vivo tumor targeting of the infrared derivative of conjugate 8 using the AtT20 xenograft-bearing mice. 
Animals were injected intravenously with 1 mg/kg of conjugate 10 and whole-body images were taken at the indicated timepoints. 
In vivo antitumor activity 
On the basis of the above results, the in vivo antitumor effi-
cacy of conjugate 8 was evaluated in AtT20 tumor-bearing 
mice. The maximum tolerated dose of the conjugate was de-
termined by dose escalation experiments. The compound was 
well tolerated up to 10 mg/kg, the highest tested dose (data not 
shown). Mice were treated with compound 8 (5 mg/kg) once 
weekly for 3 weeks and the tumor volume was compared to 
groups treated with vehicle (2% DMSO in water) or a mixture 
of unconjugated cryptophycin and octreotide (Figure S3). 
However, no therapeutic benefit could be observed upon ad-
ministration of 8. The lack of activity presumably is attributed 
to insufficient payload release (vide infra).  
Cathepsin B stability 
Cleavage of the conjugate 8 by cathepsin B was studied to 
elucidate the reasons for the lack of in vivo efficacy (Figure 3). 
The compound was highly stable in the buffer used for the 
experiment in the absence of enzyme (90% remaining after 6 
hours of incubation) but it was readily cleaved upon addition 
of cathepsin B (1 U/mL). A small amount of compound was 
already metabolized at t = 0, suggesting a high reactivity of 
the enzyme towards conjugate 8, which was confirmed by the 
  
fast decrease of the substrate during the first hour of incuba-
tion. As expected, the enzymatic cleavage led to the formation 
of Gly-Pro-Cry-55gly. However, the release of this metabolite 
was not followed by a self-immolation of the dipeptide, as no 
cryptophycin-55 glycinate (3) was found. Further qualitative 
analysis did not show the presence of other metabolites (e.g. 
cryptophycin-55, cryptophycin-52). The cytotoxicity of the 
metabolite was evaluated using the same protocol than the 
conjugate and free drug in AtT20 cells. The IC50 value of the 
metabolite was maintained in the low nanomolar range (6.05 
nM) and was comparable to the free payload 3 and conjugate 
8.
 
Figure 3. Cathepsin B cleavage and self-immolation mechanism 
(top) and in vitro stability of conjugate 8 in presence of cathepsin 
B and quantification of the main metabolite (bottom). Compound 
8 (5 µM) was rapidly cleaved in the presence of the enzyme (1 
U/mL) already at t0, releasing the drug containing metabolite Gly-
Pro-Cry-55gly. 
CONCLUSIONS 
Here we validate octreotide as an appropriate delivery vehi-
cle to tumors overexpressing SSTR2 and cryptophycin-55 
glycinate as payload. The generated conjugates with crypto-
phycin showed good binding affinity to the receptor. The di-
peptide spacer between the enzyme-labile moiety and the drug 
largely influenced the metabolism and cytotoxicity. While the 
conjugate containing the dipeptide Pro-Gly showed instability 
in plasma and reduced cytotoxicity compared to the free drug, 
the product with the Gly-Pro sequence was highly stable and 
its cytotoxicity was comparable to the unconjugated payload. 
The replacement of the payload for the infrared fluorophore 
Cy5.5 did not alter the binding properties and the labeled 
compound was internalized selectively by the AtT20 cells. 
The homing properties of 10 were studied in nude mice bear-
ing AtT20 tumors. Pharmacokinetic and in vivo imaging stud-
ies showed that, upon i.v. injection, a fluorescent signal be-
comes rapidly associated with the tumor and persists there for 
many days despite very rapid clearance of the conjugate from 
circulation. This observation points to a fundamental differ-
ence of the peptide conjugate with respect to antibody-drug 
conjugates. While the latter have long plasma half-lives and 
only slowly penetrate into tumor tissues, peptide conjugates 
are small enough to rapidly reach their intra-tumoral targets, 
where they can be trapped due to specific interaction with the 
cognate receptor. The unbound conjugate gets rapidly cleared, 
mostly by glomerular filtration, thereby avoiding unwanted 
toxicities to normal tissues. ADCs, in contrast will expose the 
whole organism to released toxin for a long period of time, 
thereby potentially giving rise to side effects. In line with this 
notion, several ADCs directed against solid tumor targets have 
recently failed in the clinic due to low therapeutic indices. Our 
octreotide-cryptophycin conjugate, albeit being well tolerated 
and having the desired pharmacokinetic profile, did not show 
any therapeutic benefit upon administration at the selected 
dosing regimen. Cathepsin B cleavage studies proved efficient 
enzymatic cleavage of the sensitive dipeptide Val-Cit and 
release of the metabolite Gly-Pro-Cry-55gly, which did not 
detectably react by further self-immolation to release crypto-
phycin-55 glycinate under the test conditions. It is possible 
that the in vitro cytotoxicity of the obtained metabolite is in-
sufficient to lead to a sustained in vivo efficacy. The transla-
tion of the promising in vitro results to an in vivo model is 
currently under investigation. The system might benefit from a 
different linker, which affords efficient release of the free pay-
load and longer residence in vivo. 
EXPERIMENTAL SECTION 
Synthesis of N3-PEG4-Val-Cit-Pro-Gly (1) and N3-
PEG4-Val-Cit-Gly-Pro (2): Self-immolative linkers 1 and 2 
were synthesized manually using standard SPPS. First amino 
acid was loaded to chlorotrityl resin by reacting the corre-
sponding amino acid (1.5 eq) and DIPEA (3 eq) in anhydrous 
DCM for 3 h at RT. Then, MeOH (1 mL) was added, the resin 
stirred 10 minutes and then was washed with DMF (6 x 1 min) 
and DCM (1 x 1 min). The resin was dried with diethyl ether 
and Fmoc test was performed to check the loading. Elongation 
of the sequence was performed by sequential Fmoc removal 
and coupling of the corresponding amino acid. Fmoc group 
was removed by treating the resin with a mixture of piperi-
dine/DMF (3:7, 2 + 10 min). Coupling of the Fmoc amino 
acids (4 eq) was performed by treatment with DIC (4 eq) and 
Oxyma (4 eq) in DMF under stirring at RT for 2 h. 13 (2 eq) 
coupling was performed with DIC (2 eq), Oxyma (2 eq) and 
DIPEA (2 eq) in DMF under stirring at RT for 6 h. Final 
cleavage was performed with TFA/H2O/TIS (95:2.5:2.5) for 2 
h at RT. Product was purified by reversed-phase HPLC 
(method P1). 1: HPLC-MS: tR = 5.33 min, >99% purity (λ = 
220 nm), m/z = 702.43 (702.38 [M+H]+); 2: HPLC-MS: tR = 
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5.52 min, 91% purity (λ = 220 nm), m/z = 702.48 (702.38 
[M+H]+). 
Synthesis of N3-PEG4-Val-Cit-Pro-Gly-Cry-55gly (4): 
Cryptophycin-55 glycinate trifluoroacetate prepared as previ-
ously described44 (5 mg, 5.7 µmol, 1 eq), 1 (8 mg, 11.4 µmol, 
2 eq), PyBOP (5.9 mg, 11.4 µmol, 2 eq) and HOBt∙H2O (2 
mg; 12.8 µmol; 2.25 eq) were placed under argon atmosphere 
and dissolved with anhydrous DMF (0.5 mL). DIPEA (2.5 µL, 
14.3 µmol, 2.5 eq) was added and the reaction mixture was 
stirred at RT for 4 h. Then, the solution was directly purified 
by RP-HPLC (method P3). Freeze-drying of fractions contain-
ing the product afforded 4 (4.5 mg, 54% yield) as white pow-
der. HPLC-MS: tR = 9.57 min, >99% purity (λ = 220 nm), m/z 
= 1445.69 (1445.65 [M+H]+); 723.35 (723.33 [M+2H]2+). 
HRMS (ESI-MS): m/z calculated for C67H100Cl2N12O19 
[M+2H]2+ 723.3297; found 723.3291. 
Synthesis of N3-PEG4-Val-Cit-Gly-Pro-Cry-55gly (5): 
Cryptophycin-55 glycinate trifluoroacetate (10 mg, 0.011 
mmol, 1 eq), 2 (16 mg, 0.022 mmol, 2 eq), PyBOP (11.9 mg, 
0.022 mmol, 2 eq) and HOBt∙H2O (3.9 mg; 0.026 mmol; 2.25 
eq) were placed under argon atmosphere and dissolved with 
anhydrous DMF (0.5 mL). DIPEA (5 µL, 0.028 mmol, 2.5 eq) 
was added and the reaction mixture was stirred at RT for 4 h. 
Then, the solution was directly purified by RP-HPLC (method 
P2). Freeze-drying of fractions containing the product afford-
ed 5 (13 mg, 79% yield) as white powder. HPLC-MS: tR = 
9.54 min, 97% purity (λ = 220 nm), m/z = 1445.67 (1445.65 
[M+H]+); 723.34 (723.33 [M+2H]2+). HRMS (ESI-MS): m/z 
calculated for C67H100Cl2N12O19 [M+2H]2+ 723.3297; found 
723.3291. 
Synthesis of 4-pentynoyl-octreotide (α-CH2CH2C≡CH) 
(6): Octreotide acetate was ε-mono-Boc-protected as previous-
ly described.49 Octreotide(ε-Boc) (69 mg, 0.056 mmol, 1 eq), 
was dissolved in a 1:1 solution of ethanol and 0.2 M borate 
buffer (pH = 8.5) to a final concentration of 2 mg/mL. Then, 
4-pentynoic acid succinimidyl ester (109 mg, 0.56 mmol, 10 
eq) was added and the solution was stirred at RT overnight. 
The crude was purified by RP-HPLC (method P1) to obtain 
Octreotide (ε-Boc, α-CH2CH2C≡CH) (53 mg, 80% yield). 
Finally, the Boc group was removed with TFA/H2O/TIS 
(95:2.5:2.5) for 5 min at RT, the solvents were immediately 
evaporated, and the crude residue was purified by RP-HPLC 
(method P1) to give 6 (46 mg, 85% yield) as a white powder 
after freeze-drying. HPLC-MS: tR = 5.97 min, 96% purity (λ 
= 220 nm), m/z = 1099.47 (1099.47 [M+H]+); 550.24 (550.24 
[M+2H]2+). HRMS (ESI-MS): m/z calculated for 
C54H71N10O10S2 [M+H]+ 1099.4740; found 1099.4775; calcu-
lated for C54H72N10O10S2 [M+2H]2+ 550.2406; found 
550.2429. 
Synthesis of 7: Azide 4 (6 mg, 0.004 mmol, 1 eq), alkyne 6 
(5 mg, 0.004 mmol, 1 eq), CuSO4ꞏ5H2O (0.6 mg, 0.6 eq) and 
sodium ascorbate (0.3 mg, 0.4 eq) were placed under argon 
atmosphere and dissolved with a degassed solution of 
DMF/H2O (1:1, 0.5 mL). The solution was stirred for 24 h at 
40 ºC and was directly purified by RP-HPLC (method P4). 
Freeze-drying of desired fractions afforded 7 (5.6 mg, 51% 
yield) as white powder. HPLC-MS: tR = 7.47 min, 98% purity 
(λ = 220 nm), m/z = 1272.62 (1272.56 [M+2H]2+); 848.75 
(848.71 [M+3H]3+). HRMS (ESI-MS): m/z calculated for 
C121H171Cl2N22O30S2 [M+3H]3+ 848.7111; found 848.7122. 
Synthesis of 8: Azide 5 (10.8 mg, 0.007 mmol, 1 eq), al-
kyne 6 (8.5 mg, 0.007 mmol, 1 eq), CuSO4ꞏ5H2O (1.1 mg, 0.6 
eq) and sodium ascorbate (0.6 mg, 0.4 eq) were placed under 
argon atmosphere and dissolved with a degassed solution of 
DMF/H2O (1:1, 0.5 mL). The solution was stirred for 24 h at 
40 ºC and was directly purified by RP-HPLC (method P2). 
Freeze-drying of desired fractions afforded 8 (12 mg, 60% 
yield) as white powder. HPLC-MS: tR = 7.50 min, 98% purity 
(λ = 220 nm), m/z = 1272.58 (1272.56 [M+2H]2+); 848.72 
(848.71 [M+3H]3+). HRMS (ESI-MS): m/z calculated for 
C121H171Cl2N22O30S2 [M+3H]3+ 848.7111; found 848.7139. 
Binding affinity: Compounds were solubilized with 100% 
DMSO at a concentration of 10 mM and diluted with assay 
buffer (25 mM HEPES pH 7.4, 5 mM MgCl2, 1 mM CaCl2, 10 
µg/mL Saponin, 0.5% protease free BSA). The dilution of test 
compound (50 µL, maximum final DMSO concentration 3%), 
radioligand 3-[125I] iodotyrosyl11 Somatostatin 14 (Perkin 
Elmer, NEX389, 25 µL, 0.4 nM) and membrane extract (re-
combinant CHO-K1-SST2 (NP_001041.1), 25 µL, 0.2 µg) 
were successively added to a 96-well plate and incubated at 25 
ºC for 60 min. It was filtered over GF/B Unifilter plate (Perkin 
Elmer, 6005177, pre-soaked in 0.5% PEI for 2 h at room tem-
perature) with a Filtermate Harvester (Perkin Elmer). After 
rinsing the filters 6 times with 0.5 mL of ice-cold washing 
buffer (25 mM HEPES pH 7.4, 5 mM MgCl2, 1 mM CaCl2), 
50 µL of Microscint 20 (Packard) was added to the filters and 
the samples were incubated 15 min on an orbital shaker and 
then counted with a TopCount™ for 1 min/well. Binding af-
finity was determined in duplicates by plotting the dose-
response data to a nonlinear regression with variable slope.  
In vitro cytotoxicity: To evaluate the cytotoxicity of conju-
gates and metabolites, AtT20/D16v-F2 murine pituitary tumor 
cells obtained from American Type Culture Collection 
(ATCC, Bethesda, MD, USA) were used. Cell viability was 
determined by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) assay. Briefly, cells in DMEM 
supplemented with 10% FBS, 1% L-glutamine and 1% peni-
cillin/streptomycin, were seeded in 96-well culture plates 
(3000 cells/well) and incubated overnight in a humidified, 37 
°C, 5% CO2 atmosphere to allow adherence. The following 
day cells were treated with serial dilutions of each compound 
starting at 100 nM for free drugs and 1000 nM for each one of 
the conjugates and incubated as described for 2 h. 0.1% 
DMSO served as a control. After incubation, cells were 
washed once, media replaced, and incubation continued for 
further 70 h. At the end of treatment, 5 µL of MTT solution (5 
mg/mL in deionized H2O, Sigma #M5655) was added to each 
well and cells were incubated for another 2 hours. Finally, 100 
µL of lysis buffer (10% SDS, 10 mM HCl) was added, and 
cells placed in the incubator overnight for the formazan crystal 
solubilization. Absorbance at 540 nm was measured using a 
FLUOstar Omega (BMG Labtech) microplate reader and the 
growth inhibition ratio was calculated. Blank controls detect-
ing cell-free media absorbance were performed in parallel. 
Three experimental replicates were used. The half-maximal 
inhibitory concentration values (IC50) were obtained from 
viability curves using GraphPad Prism 6. Cell viability was 
expressed as percentage relative to the respective control con-
ditions. 
  
Plasma stability: The sample preparation and the metabolic 
analysis of the conjugates was carried out similarly to the pre-
viously described method.50 Shortly, in a 96-well plate each 
conjugate and the control compound, procaine (3 mM, stock 
solution in DMSO) in three replicates were diluted with 250 
μL of plasma to give a 3 µM concentration and incubated at 
37 °C. At each sample collecting time point an aliquot of 30 
µL was transferred into a 96-deep well plate and the reaction 
was stopped with 120 µL of acetonitrile containing 0.1% for-
mic acid and 0.4 µg/mL of warfarin as internal standard (IS). 
This mixture was centrifuged at 1100 ×g for 30 min at 4 °C 
and 50 µL of supernatant was transferred into a clean 96 deep-
well plate and diluted with 50 µL of 0.1% formic acid in wa-
ter. Samples were stored at -80 °C until analyses. Stability was 
determined based on LC-HRMS analysis of the disappearance 
of the compound as a function of incubation time, using area 
ratio (analyte peak area vs internal standard peak area). The 
elimination constant k is calculated by plotting mean disap-
pearance values on a semi-logarithmic scale and fitting with a 
best fit linear regression. The half-life (t1/2) expressed in hours 
is derived using equation:  t1/2 = ln2/(-k). 
Receptor and conjugate internalization: For the immuno-
fluorescence studies of SSTR2 internalization, AtT20/D16v-
F2 cells were grown overnight in 8-well chamber slides 
(Nunc® Lab-Tek®, Sigma-Aldrich, St. Louis, MO) previously 
coated with poly-D-lysine (10 µg/mL, Sigma-Aldrich, St. Lou-
is, MO). Cells were treated with concentrations ranging from 
10 to 1000 nM of either octreotide-cryptophycin conjugates or 
with octreotide as positive control, for 30 min at 37 C. To 
stop the internalization process and fix the cells, wells were 
rinsed twice with cold PBS and fixed with ice cold methanol 
for 7 min. Then, the non-specific binding sites were blocked 
with PBS containing 10% fetal bovine serum for 60 min at 
room temperature, and cells were incubated for another 60 
min with rabbit anti-SSTR2 primary antibody (UMB-1, 
Abcam #ab134152) diluted 1:200 in blocking solution. Next, 
wells were rinsed 3 times for 5 min with PBS followed by 
incubation in the dark with the secondary antibody Alexa Flu-
or 488 goat anti-rabbit diluted 1:600 in blocking solution for 
60 min. Nuclei were visualized by DAPI staining (1 µL/mL in 
PBS, Tocris) for 15 min. Finally, wells were rinsed, chambers 
removed, and coverslips mounted with Mowiol 4-88 antifad-
ing solution (Sigma). Images were generated using the Zeiss 
AxioImager upright epifluorescence microscope with a 100× 
oil immersion objective. The real-time internalization of the 
labeled conjugate 10 was acquired using a Zeiss LSM880 con-
focal microscope coupled to an environmental chamber allow-
ing a 37 C, 5% CO2 atmosphere. Briefly, the AtT20/D16v-F2 
murine pituitary tumor cells that express high levels of SSTR2 
and the human epithelial lung carcinoma A549 cells with low 
SSTR2 expression were grown overnight as described above. 
On the day of the experiment, either 1 µM of the fluorescently 
labeled conjugate 10 alone or a mixture of that with 100-fold 
excess of free octreotide were prepared in phenol red-free 
media (1% DMSO final) and warmed up to 37 C. Image ac-
quisition was performed using a 40× water immersion objec-
tive and started shortly after the solutions were added to the 
cells. One frame was acquired every 30 s for a total of 60 
frames. Brightfield was used to visualize the cellular bodies.  
Pharmacokinetics: To evaluate the pharmacokinetic profile 
of conjugate 8 and its fluorescece-labeled analog 10, four-
weeks-old female heterozygous NCR mice from Charles River 
were used. Animals were injected intravenously with 2.5 
mg/kg (in 2% DMSO in water, dosed at 0.5 mg/mL) of each 
conjugate. Terminal blood samples were collected via cardiac 
puncture from animals under deep anesthesia at different time 
points (5, 15, 30, 60, 180, and 360 min, n=3). Samples were 
rapidly transferred to lithium heparin-coated tubes, kept on ice 
and subsequently centrifuged at 2000 ×g, 4 C for 10 minutes. 
After centrifugation plasma was collected, and samples kept at 
-20 C until analyses. 
Tumor targeting studies: The fluorescence-labeled conju-
gate 10 (1 mg/kg in 2% DMSO in water) was injected intrave-
nously in nude mice bearing AtT20 tumors. At each time point 
whole body imaging was acquired using the Lago optical im-
aging system (Spectral Instruments Imaging) while mice were 
under isoflurane anesthesia (2.5%/20% O2). 
Cathepsin B degradation: An aqueous solution of L-
cysteine (0.28 M) was diluted 1:10 in acetate buffer/EDTA 1 
mM pH 5.5, to achieve a working solution of 28 mM of L-
cysteine. This solution was used to dilute cathepsin B to 1.11 
U/mL. The cathepsin B solution was pre-incubated at 37 °C 
for 15 min and then split into 45 µL aliquots in Eppendorf 
tubes, with two replicates for each incubation time. 5 µL of 
substrate solution (50 µM in MeOH/H2O (1:1)) were added to 
each tube for a final concentration of 5 µM. Tubes corre-
sponding to t0 contained 100 µL of 1% HCOOH in MeOH and 
were put in ice bath to inhibit the reaction. All the other tubes 
were incubated at 37 °C in an oscillating thermostatic bath and 
the reaction was stopped at the following incubation times: 
0.25, 0.5, 1, 2, 4 and 6 hours, as described for t0 samples. 
Samples were then centrifuged for 10 min at 14000 rpm at 4 
°C and filtered through regenerated cellulose syringe filters 
prior to injection in the HPLC/MS system. Control solutions 
containing 5 µM substrate in acetate buffer pH 5.5/EDTA 1 
mM/L-cysteine 28 mM were also prepared and incubated up to 
6 hours at 37 °C in the absence of the enzyme to check the 
substrate stability under incubation conditions. Substrates and 
their possible cleavage products (Gly-Pro-Cry-55gly, Cry-
55gly and Cry-55) were quantified via calibration curves pre-
pared in acetate buffer/EDTA/L-cysteine in the range 25-5000 
nM. 
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6. Summary 
In the last years, cancer treatment has shifted towards a targeted therapy approach. 
Antibody- and small molecule-drug conjugates have shown enhanced selectivity and 
efficacy compared to traditional chemotherapeutics. Thus, the possibility to selectively 
deliver cytotoxic agents that are highly potent but cannot be administered as stand-alone 
agents opened new opportunities. In this context, the conjugation of cryptophycin to a 
delivery vehicle could be translated in a significant antitumor activity.  
In the first part (chapter 3), the cytotoxic influence of different modifications in the para 
position of unit B was investigated. The O-methyl group was replaced by an O-
(allyloxyethyl) moiety or an O-(((azidoethoxy)ethoxy)ethoxyethyl) substituent. The 
former can be used as a precursor for an alcohol functionalized cryptophycin while the 
later can be submitted to the mild conditions of the Staudinger reduction to obtain a free 
amine. The synthesis of the modified unit B (47 and 48, Scheme 2) proceeded through a 
linear sequence of 4 steps starting with D-Tyrosine (46, Scheme 2). Then, the modified 
unit B were coupled to the unit ADC to obtain the linear cryptophycins that were then 
macrocyclized under pseudo-high dilution conditions. Subsequent diol to epoxide 
transformation led to modified cryptophycins 49 and 50.  
 
Scheme 2. Schematic synthetic route towards unit B modified cryptophycins (49-51).  
Their cytotoxicity was determined in human cervix carcinoma cell line KB-3-1 (Table 1). 
A dramatical loss of activity was observed for the analogue 49. However, compound 50 
retained the high cytotoxicity of the parent compound cryptophycin-52 (32). With these 
results in hand, compound 49 was not further investigated and alcohol deprotection of 50 
was achieved using Pd(PPh3)4 as Pd(0) source and phenylsilane as scavenger. The 
obtained cryptophycin analogue 51 was 4-fold more active than its protected cognate and 
only a 12-fold reduction compared to cryptophycin-52 was observed. Next, the 
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cytotoxicity of the compounds 50 and 51 was investigated in the MDR cell line KB-V1. 
Differently than in the non MDR KB-3-1, compound 50 was more active than 51. This 
could be attributed to the increased amphiphilicity produced for the free alcohol. 
Remarkably, compounds 50 and 51 showed an IC50 value in the low nanomolar range 
which make them promising agents to be used in targeted therapy. 
Finally, their binding affinity using molecular docking calculations was investigated. 
Cryptophycin-52 showed the highest binding energy followed by 51, 50, and 49, which 
provided a rationale for the observed cytotoxicities in KB-3-1 cells. 
Compound Cytotoxic activity  Binding energy (kJ/mol) IC50 KB-3-1 (nM) IC50 KB-V1 (nM) 
Cryptophycin-52 (32) 0.015 0.26 36.17 
49 195000 - 22.61 
50 0.748 14.5 32.20 
51 0.184 42.1 32.70 
Table 1. Biological evaluation using a cell-based assay in human cervix carcinoma (KB-3-1) and its MDR 
subclone (KB-V1), and binding energies using molecular docking for cryptophycin-52 (32) and novel 
analogues (49-51). 
In the second part (chapters 4 and 5), cryptophycin-55 glycinate was conjugated to small 
molecules targeting different antigens. The glycinate ester of cryptophycin-55 was 
observed to provide stability, maintained high cytotoxicity in vitro, and showed antitumor 
activity in vivo. The recent conjugation of this drug to an antibody and the promising in 
vitro properties showed from the obtained ADC, motivated us to explore its usage in 
conjugation to small molecules. 
In chapter 4, cryptophycin-55 glycinate was conjugated to the protease sensitive Val-Cit 
dipeptide including para-aminobenzoyl moiety as self-immolative spacer via carbamate 
bond. A maleimide moiety was included in the N-terminus to allow conjugation to the 
homing device via Michael addition. Conjugation to the bidentate acetazolamide 
targeting carbonic anhydrase IX was successfully achieved, and the final conjugate was 
obtained in excellent purity (52, Figure 24). 
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Figure 24. Molecular structures of acetazolamide conjugates targeting CAIX using MMAE (25) or 
cryptophycin-55 glycinate (52) as payload. 
The biological activity of 52 was compared to the lead compound 25 (Figure 24). 
Compound 52 showed a binding affinity of 3.4 nM using surface plasmon resonance 
(SPR) towards recombinant human CAIX, which was in the same range than the isolated 
ligand (Kd = 2.6 nM) and slightly better than lead compound 25 (Kd = 10 nM). The 
cytotoxicity of 52 was investigated in an in vitro cell-based assay using the renal cell 
carcinoma SKRC-52. Conjugate 52 showed a prodrug behavior characteristic of 
noninternalizing conjugates which is translated to a reduced cytotoxicity compared to the 
activity of the free payload cryptophycin-55 glycinate (IC50 = 7.9 nM). Cryptophycin-55 
glycinate was less potent than monomethyl auristatin E (MMAE, IC50 = 1.5 nM) used in 
the conjugate 25. Finally, the therapeutic activity of 52 was studied in nude mice bearing 
SKRC-52 tumors and compared to 25 using an optimal and safe dose of 250 nmol/kg 
based on previous biodistribution studies. Mice that were treated with the cryptophycin-
acetazolamide conjugate (52) enjoyed a therapeutic benefit with a slower tumor growth 
compared with the control group (saline). However, the activity was remarkably inferior 
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to the lead compound 25, which can be attributed to the lower cytotoxicity of the free 
payload in this concrete cell line. 
 
Figure 25. Biological evaluation of conjugate 52. (A) in vitro toxicity of conjugate 52 and cryptophycin-55 
glycinate in SKRC-52 renal carcinoma. (B) SPR analysis of 52 to immobilized CAIX. (C) Tumor volume 
changes for different treatment groups in nude mice bearing SKRC-52 tumors.  
In chapter 5, cryptophycin-55 glycinate was conjugated to the protease sensitive dipeptide 
Val-Cit including a novel diketopiperazine self-immolative linker based on the dipeptide 
Pro-Gly or Gly-Pro. The conjugation was done via amide bond and the linker included 
an azide moiety to allow conjugation to alkyne functionalized octreotide targeting the 
somatostatin receptor 2 (SSTR2) by click chemistry. Conjugation was successfully 
achieved using copper(I)-catalyzed alkyne-azide cycloaddition (CuAAC), and two 
cryptophycin-octreotide conjugates (53 and 54, Figure 26), differing in their self-
immolative moiety, were successfully obtained.  
 
Figure 26.  Molecular structures of octreotide conjugates targeting SSTR2 using cryptophycin as payload (53 
and 54). 
Their binding affinity against SSTR2 was measured using radioligand binding 
displacement. 53 and 54 showed a low nanomolar IC50 affinity (0.62 nM and 1.3 nM, 
respectively), comparable to the isolated octreotide ligand (IC50 = 0.5 nM). 
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The bioactivity of 53 and 54 was evaluated with an in vitro cytotoxicity assay using AtT20 
pituitary mouse cells (Figure 27). The activity was remarkably different depending on the 
linker. Conjugate 54 retained the high cytotoxicity of the free payload (IC50 of 8.37 nM 
and 3.53 nM, respectively), while compound 53 was remarkably less active (IC50 = 51.23 
nM). 
The stability of conjugates 53 and 54 was studied in murine and human plasma (Figure 
27). The resistance to the proteases of plasma was largely influenced by the self-
immolative moiety. Compound 53 was especially labile to murine plasma with a half-life 
of 30 min while 54 was remarkably stable (t1/2 > 24 h). In human plasma they exhibited 
similar stability with half-lives of 23 h and 24 h for 53 and 54, respectively. 
  
Figure 27. In vitro cytotoxicity of cryptophycin-55 glycinate, conjugates 53 and 54 in AtT20 cell line (left) 
and stability of conjugates 53 and 54 in murine and human plasma (right). 
Both conjugates induced the internalization of SSTR2 at 1000 and 10 nM. The homing 
properties of lead compound 54 were studied by replacing cryptophycin-55 glycinate with 
the infrared dye Cy5.5 (55, Figure 28). 
 
Figure 28. Molecular structure of octreotide-Cy5.5 conjugate 55. 
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In vitro cell imaging of 55 in AtT20 (SSTR2 positive) cells showed effective 
internalization after only 10 min of incubation. The internalization was efficiently 
competed by 100-fold excess of octreotide and no internalization was observed in A549 
(SSTR2 negative) cell line, proving the receptor mediated endocytosis of the conjugate. 
The tumor-targeting ability of 55 was evaluated in nude mice bearing AtT20 tumors 
(Figure 29). The compound was administered intravenously at 1 mg/kg and whole-body 
images at different time points were taken. A high percentage of compound could be 
observed in clearing organs (i.e. liver and kidneys) at early time points. However, 
preferential accumulation of conjugate 55 in the tumor over the healthy tissues that are 
not involved in the compound excretion could be observed and the compound showed 
good homing properties with detection in the tumor up to 7 days. 
The therapeutic activity of 54 was evaluated in AtT20 tumor-bearing mice. Dose 
escalation of the compound showed good tolerability up to 10 mg/kg (the highest tested 
dose). Mice were treated with compound 54 once weekly at 5 mg/kg for 3 weeks and the 
tumor volume was compared to vehicle (Figure 29). No therapeutic benefit could be 
observed at the selected regimen. 
 
Figure 29. In vivo tumor targeting of 55 (left) and in vivo antitumor efficacy of conjugate 54 (right) in AtT20 
xenografts. 
The drug release of 54 by cathepsin B was studied to understand the lack of efficacy in 
vivo. The compound was rapidly metabolized in the presence of enzyme and the expected 
Gly-Pro-Cry-55gly metabolite was released. This metabolite was not further transformed 
by self-immolation of the dipeptide. The cytotoxicity of Gly-Pro-Cry-55gly was 
evaluated in a cell-based assay using AtT20 cells and it showed low nanomolar activity 
(IC50 = 6.05 nM). The high in vitro cytotoxicity of the metabolite indicates that the lack 
of in vivo efficacy is unlikely to be related to the absence of self-immolation. 
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1) General methods  
All reactions requiring anhydrous conditions were performed under argon atmosphere. DMF 
was dried over 4 Å molecular sieves, CH2Cl2 was distilled from CaH2, THF and DME were 
distilled from sodium/benzophenone. Anhydrous acetone and ethylene glycol were purchased 
from commercial sources. All the other chemicals and solvents (HPLC-grade or reagent-grade 
quality), unless otherwise stated, were purchased from commercial sources and used without 
further purification. Silica for flash chromatography was purchased from Macherey-Nagel 
40–63 μM (230-400 mesh). Reactions were monitored by thin layer chromatography using 
aluminium-backed plates coated with silica gel 60 F254 from Merck; visualization was ac-
complished with UV light or staining with potassium permanganate or cerium molybdate so-
lution. 
 
Liquid chromatography–mass spectrometry 
LC–MS was conducted using an Agilent 1200 series consisting of an autosampler, degasser, 
binary pump, column oven and diode array detector coupled to an Agilent 6220 accurate-mass 
TOF MS. A Hypersil Gold C18 (150 mm × 2.1 mm, 3 μm particle size) was used as column.  
Eluent A: H2O/CH3CN/HCOOH = 95/5/0.1 and eluent B: H2O/CH3CN/HCOOH = 5/95/0.1. 
Method A:  
Flow rate: 300 µl/min  
 0 min  100% A  0% B 
 10 min  2% A  98% B 
 11 min  2% A  98% B 
 11.5 min 100% A 0% B 
 15 min  100% A 0% B 
 
High-resolution mass spectrometry 
High resolution mass spectra were recorded on an Agilent 6220 accurate-mass TOF LC/MS. 
Samples were injected through an Agilent 1200 series. Hypersil Gold C18 (50 mm × 2.1 mm, 
1.9 μm particle size) was used as a column. Same solvents than HPLC–MS were used and a 
linear gradient from 0 to 98% B over 4 minutes was employed.  
 S3 
The mass spectrometer was externally calibrated using Agilent tuning mix prior to measure-
ment.   
 
NMR spectroscopy 
NMR spectra were recorded on a Bruker Avance 400 (
1
H: 400 MHz, 
13
C: 100 MHz), Avance 
500HD (
1
H: 500 MHz, 
13
C: 126 MHz) or Avance 600 (
1
H: 600 MHz, 
13
C: 151 MHz) at 298 
K. Chemical shifts were referenced to residual nondeuterated solvent signal (CDCl3: 
1
H: 7.26 
ppm; 
13
C: 77.16 ppm). Coupling constants (J) are reported in Hz with the following abbrevia-
tions used to indicate splitting: s = singlet, d = doublet, t = triplet, q = quartet, m = multiplet, 
br = broad signal. The acronyms uA, uB, uC and uD describe signals pertaining to cryptophy-
cin units A–D.  
Cell lines 
Biological tests: The KB-3-1 cells were cultivated as monolayer in DMEM (Dulbecco’s mod-
ified Eagle medium) with glucose (4.5 g/L), L-glutamine, sodium pyruvate, phenol red (PAA) 
and supplemented with 10% foetal calf serum (FCS). The cells were maintained at 37 °C and 
5.3% CO2/humidified air. On the day before the test, the cells were detached with tryp-
sin/ethylenediaminetetraacetic acid (EDTA) solution (0.05% / 0.02% in phosphate buffered 
saline solution PBS; PAA) and plated in sterile 96-well plates in a density of 10 000 cells in 
100 µL medium per well. The dilution series of the compounds were prepared from stock 
solutions in DMSO of concentrations of 1 mM or 10 mM. The stock solutions were diluted 
with culture medium (10% FCS). The dilution (100 µL) was added to the wells. Each concen-
tration was tested in six replicates. The control contained the same concentration of DMSO as 
the first dilution. After incubation for 72 h at 37 °C and 5.3% CO2/humidified air, 30 µL of an 
aqueous resazurin solution (175 µM) was added to each well. Again, the cells were incubated 
at the same conditions for 6 h. Then the fluorescence was measured using a TECAN infinite 
M200. The excitation was effected at a wavelength of 530 nm, whereas the emission was rec-
orded at a wavelength of 588 nm. The IC50 values were calculated as a sigmoidal dose re-
sponse curve using GraphPad Prism (version 4.03). The IC50 values equal the drug concentra-
tions, at which vitality is 50%. 
Docking and molecular dynamic simulation 
The -tubulin structure was obtained from protein data bank (pdb: 1jff). The -subunit of 
the protein was removed, the -subunit was modified by adding the missing hydrogens and 
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the ligand (taxol) was removed. Structures of the different tested cryptophycin derivatives 
were built by Yasara structure with the correct stereochemistry. Both the beta subunit of tubu-
lin and cryptophycin derivatives were energy minimized using the Yasara2 force field before 
using in further experiments.  
Docking was performed by Yasara structure using Autodock [1], the simulation cell was de-
fined around the vinca domain residues of the energy minimized beta subunit for docking of 
all cryptophycin derivatives. Docking results were analysed based on the B-factor (binding 
energy) calculated by Yasara, compounds with correct positioning and high binding energies 
were used for further analysis. 
Molecular dynamic simulation was done by Yasara structure; the selected docking modes 
were used for simulation. Simulation cell was extended 10 Å around the whole structure and 
filled with water of 0.99 g ml
−1
 density and randomized molecule orientation, AMBER15IPQ 
with its default parameters was used as force field for running the simulation up to 1 ns. 
Simulation was also performed on the Apo structure for comparative analysis using same pa-
rameters. 
Table S1: Interaction of the cryptophycin derivatives with key amino acid residues within the 
vinca domain. 
Inhibitor Subunit
*
 Hydrophobic contact Pi interaction 
2 
A 
S174, Y210, V177, 
Y224 
Y210 
B Y210, E207, D211 Y210 
22 
C K176 
– 
D V177 
23 
A 
K176, S174, V177, 
E207 
Y210 
B 
S174, Y224, V177, 
D179 
– 
24 
A V177, S178 
– C P222, Y224 
D E207, Y224 
* 
subunit of cryptophycin molecule. 
 
 
 S5 
2) Synthesis of modified unit B  
2-(2-(2-Azidoethoxy)ethoxy)ethan-1-ol (4) 
 
Triethylene glycol (10 g, 66.6 mmol, 1 equiv) was monotosylated as previously described and 
used without column chromatography purification [2]. The crude was dissolved in anhydrous 
DMF (28 mL) under inert atmosphere and NaN3 (1.83 g, 28.2 mmol, 2 equiv) was added. The 
solution was stirred overnight at 70 ºC. Then, the DMF was removed under reduced pressure 
and the residue was dissolved in DCM (100 mL) and HCl 0.5 M (100 mL), the layers were 
separated and the aqueous layer was further extracted with DCM (100 mL). The combined 
organic layers were dried over Na2SO4 and the solvent was removed under reduced pressure. 
The crude was purified by column chromatography using DCM/MeOH (99:1 → 96:4) as elu-
ent to afford 1.75 g (60% yield) of 4 as a colourless oil.  
1
H-NMR (400 MHz, CDCl3): δ (ppm) = 3.40 (t, J = 5.0 Hz, 2H, CH2N3), 3.62 (m, 2H, 
CH2CH2OH), 3.67-3.70 (m, 6H, CH2), 3.75 (m, 2H, CH2OH). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) = 50.7, 61.8, 70.1, 70.4, 70.7, 72.5. 
 
2-(2-(2-Azidoethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (5) 
 
2-(2-(2-Azidoethoxy)ethoxy)ethan-1-ol (1.67 g, 9.53 mmol, 1 equiv) was monotosylated as 
previously described and the crude was purified by column chromatography using hex-
ane/ethyl acetate (7:3) as eluent to obtain 2.07 g (66% yield) of 5 as colourless oil. 
1
H-NMR (400 MHz, CDCl3): δ (ppm) = 2.44 (s, 3H, CH3), 3.36 (t, J = 5.1 Hz, 2H, CH2N3), 
3.60 (s, 4H, CH2), 3.64 (m, 2H, CH2), 3.70 (m, 2H, CH2CH2OSO2), 4.16 (m, 2H, CH2OS2), 
7.34 (d, J = 8.0 Hz, 2H, C
ar
H), 7.79 (d, J = 8.3 Hz, 2H, SO2C
ar
C
ar
H). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) = 21.8, 50.8, 68.9, 69.4, 70.2, 70.7, 70.9, 128.1, 
129.9, 133.1, 144.9. 
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1-Azido-2-(2-(2-iodoethoxy)ethoxy)ethane (6) 
 
2-(2-(2-Azidoethoxy)ethoxy)ethyl 4-methylbenzenesulfonate (1.2 g, 3.64 mmol, 1 equiv) and 
NaI (2.18 g, 14.64 mmol, 4 equiv) were dissolved in anhydrous acetone (28 mL) under inert 
atmosphere and it was refluxed overnight. Then, the solvent was removed under reduced 
pressure and the crude was dissolved in DCM (100 mL), washed with H2O (100 mL) and 
brine (100 mL). The organic layer was dried over Na2SO4 and the solvent was removed under 
reduced pressure to obtain 0.87 g (84% yield) of 6 as colourless oil.    
1
H-NMR (400 MHz, CDCl3): δ (ppm) = 3.27 (t, J = 6.8 Hz, 2H, CH2I), 3.40 (t, J = 5.0 Hz, 
2H, CH2N3), 3.68-3.71 (m, 6H, CH2), 3.77 (t, J = 6.8 Hz, 2H, CH2CH2I). 
 
2-(Allyloxy)ethyl 4-methylbenzenesulfonate (8) 
 
2-Allyloxyethanol (5 g, 48.9 mmol, 1 equiv) was tosylated as previously described and the 
crude product was purified by column chromatography using PE/EtOAC (8:2) as eluent to 
obtain 8.48 g (68% yield) of 8 as colourless oil.  
1
H-NMR (500 MHz, CDCl3): δ (ppm) = 2.44 (s, 3H, CH3), 3.62 (t, J = 4.8 Hz, 2H, 
CH2OAllyl), 3.93 (d, J = 5.6 Hz, 2H, OCH2CH), 4.16 (t, J = 4.8 Hz, 2H, CH2OSO2), 5.15 (dd, 
J = 10.6, 1.5 Hz, 1H, CH=CH
cis
H
trans
), 5.21 (dd, J = 17.3, 1.5 Hz, 1H, CH=CH
cis
H
trans
), 5.81 
(ddt, J = 16.3, 10.8, 5.6 Hz, 1H, CH=CH2), 7.33 (d, J = 8.0 Hz, 1H, CH
ar
), 7.79 (d, J = 8.0 Hz, 
1H, CH
ar
). 
13
C-NMR (126 MHz, CDCl3): δ (ppm) = 21.7, 67.5, 69.4, 72.2, 117.5, 128.1, 129.9, 133.1, 
134.2, 144.9. 
 
3-(2-Iodoethoxy)prop-1-ene (9) 
 
2-(Allyloxy)ethyl 4-methylbenzenesulfonate (8.45 g, 33.0 mmol, 1 equiv) and NaI (19.8 g, 
131.9 mmol, 4 equiv) were dissolved in anhydrous acetone (65 mL) under inert atmosphere 
and it was refluxed overnight. Then, the solvent was removed under reduced pressure and the 
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crude was dissolved in DCM (150 mL), washed with H2O (150 mL) and brine (150 mL). The 
organic layer was dried over Na2SO4 and the solvent was removed under reduced pressure to 
obtain 5.32 g (76% yield) of 9 as colourless oil.    
1
H-NMR (500 MHz, CDCl3): δ (ppm) = 3.26 (t, J = 6.8 Hz, 2H, CH2I), 3.70 (t, J = 6.8 Hz, 
2H, CH2CH2I), 4.04 (d, J = 5.6 Hz, 2H, OCH2CH), 5.21 (d, J = 10.4 Hz, 1H, CH=CH
cis
H
trans
), 
5.30 (dd, J = 17.3, 1.5 Hz, 1H, CH=CH
cis
H
trans
), 5.91 (ddt, J = 16.7, 11.1, 5.6 Hz, 1H, 
CH=CH2). 
13
C-NMR (126 MHz, CDCl3): δ (ppm) = 3.0, 70.8, 71.9, 117.7, 134.5. 
 
Boc-D-Tyr(3-Cl,(OCH2CH2)3N3)-(OCH2CH2)3N3 (11) 
 
Boc-D-Tyr(3-Cl)-OH (1.1 g, 3.49 mmol, 1 equiv), K2CO3 (2.12 g, 15.35 mmol, 4.4 equiv) and 
6 (2.2 g, 7.72 mmol, 2.2 equiv) were placed under argon atmosphere, dissolved with anhy-
drous DMF (22 mL) and the solution was stirred overnight at 50 ºC. Then, it was diluted with 
EtOAc (150 mL) and H2O (150 mL), the layers were separated and the aqueous layer was 
further extracted with EtOAc (150 mL). The combined organic layers were washed with brine 
(200 mL), dried over Na2SO4 and the solvent was removed under reduced pressure. The crude 
was purified by column chromatography using PE/EtOAC (1:1) as eluent to obtain 1.88 g 
(85% yield) of 11 as colourless oil.     
1
H-NMR (400 MHz, CDCl3): δ (ppm) = 1.43 (s, 9H, (CH3)3C), 2.99 (dd, J = 14.0, 5.7 Hz, 
1H, CH2-β), 3.07 (dd, J = 14.0, 5.7 Hz, 1H, CH2-β), 3.38 (m, 4H, CH2N3), 3.65-3.72 (m, 12H, 
OCH2CH2O), 3.77-3.80 (m, 2H, OCH2), 3.90 (t, J = 4.9 Hz, 2H, C
ar
OCH2CH2), 4.16 (t, J = 
4.9 Hz, 2H, C
ar
OCH2CH2), 4.23-4.34 (m, 2H, OCH2), 4.55 (q, J = 6.3 Hz, 1H, C
α
H), 5.01 (d, 
J = 8.1 Hz, NH, 1H), 6.86 (d, J = 8.4 Hz, 1H, C
5'
H), 6.99 (dd, J = 8.4, 2.2 Hz, 1H, C
6'
H), 7.16 
(d, J = 2.2 Hz, 1H, C
2'
H). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) = 28.4, 37.2, 50.8, 50.8, 54.4, 64.6, 69.0, 69.1, 69.7, 
70.2, 70.2, 70.8, 70.8, 70.9, 71.2, 80.1, 113.8, 123.0, 128.7, 129.6, 131.3, 153.5, 155.1, 171.7. 
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Boc-D-Tyr(3-Cl,(OCH2CH2)3N3)-OH (13) 
 
11 (0.72 g, 1.14 mmol, 1 equiv) was dissolved in MeOH/THF (1:1, 6 mL total) and Li-
OH·H2O (72 mg, 1.71 mmol, 1.5 equiv) in H2O (3 mL) was added dropwise and the solution 
was stirred for 2 h at rt. Then, H2O (30 mL) was added and the pH was adjusted to 3 with 1M 
KHSO4. The solution was extracted with EtOAc (3 x 30 mL) and the combined organic layers 
were thoroughly washed with 1 M HCl (3 × 50 mL) and brine (50 mL). The organic layer was 
dried over Na2SO4 and the solvent was removed under reduced pressure to obtain 0.41 g (76% 
yield) of 13 as white solid.  
1
H-NMR (400 MHz, CDCl3, rotamers): δ (ppm) = 1.34/1.43 (2 s, 9H, (CH3)3C), 2.85 (m, 
0.3H, C
β
H
A
H
B
), 2.98 (dd, J = 14.4, 6.3 Hz, 0.7H, C
β
H
A
H
B
), 3.11 (dd, J = 14.4, 5.4 Hz, 1H, 
C
β
H
A
H
B
), 3.38 (t, J = 5.1 Hz, 2H, CH2N3), 3.67-3.70 (m, 4H, OCH2), 3.78-3.80 (m, 2H, 
OCH2), 3.91 (t, J = 5.1 Hz , 2H, C
ar
OCH2CH2), 4.16 (t, J = 5.1 Hz , 2H, C
ar
OCH2), 4.35 (m, 
0.3H, C
α
H), 4.53 (q, J = 6.5 Hz, 0.7H, C
α
H), 5.00 (d, J = 7.5 Hz, 0.7H, NH), 6.28 (br, 0.3H, 
NH), 6.87 (d, J = 8.4 Hz, 1H, C
5'
H), 7.02 (dd, J = 8.4, 2.2 Hz, 1H, C
6'
H), 7.19 (br m, 1H, 
C
2'
H). 
13
C-NMR (100 MHz, CDCl3): δ (ppm) = 28.4, 36.8, 50.8, 54.4, 69.1, 69.7, 70.2, 70.9, 71.2, 
80.6, 113.9, 123.1, 128.7, 129.5, 131.3, 153.6, 155.5, 175.4.  
 
Boc-D-Tyr(3-Cl,CH2CH2OAllyl)-OCH2CH2OAllyl (12) 
 
Boc-D-Tyr(3-Cl)-OH (1 g, 3.16 mmol, 1 equiv), K2CO3 (1.92 g, 13.90 mmol, 4.4 equiv) and 9 
(1.47 g, 6.95 mmol, 2.2 equiv) were placed under argon atmosphere, dissolved with anhy-
drous DMF (20 mL) and the solution was stirred overnight at 50 °C. Then, it was diluted with 
EtOAc (150 mL) and H2O (150 mL), the layers were separated and the aqueous layer was 
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further extracted with EtOAc (150 mL). The combined organic layers were washed with brine 
(200 mL), dried over Na2SO4 and the solvent was removed under reduced pressure. The crude 
was purified by column chromatography using PE/EtOAC (4:1) as eluent to obtain 1.24 g 
(81% yield) of 12 as colourless oil.     
1
H-NMR (500 MHz, CDCl3): δ (ppm) = 1.42 (s, 9H, (CH3)3C), 2.99 (dd, J = 14.2, 5.9 Hz, 
1H, CH2-β), 3.07 (dd, J = 14.2, 5.9 Hz, 1H, CH2-β), 3.59-3.66 (m, 2H, COOCH2CH2), 3.84 (t, 
J = 4.9 Hz, 2H, C
ar
OCH2CH2), 4.02 (d, J = 5.6 Hz, 2H, COO(CH2)2OCH2), 4.13 (d, J = 5.6 
Hz, C
ar
O(CH2)2OCH2), 4.16 (t, J = 4.9 Hz, 2H, C
ar
OCH2), 4.22-4.26 (m, 1H, COOCH
A
H
B
), 
4.30-4.34 (m, 1H, COOCH
A
H
B
), 4.55 (q, J = 6.4 Hz, 1H, C
α
H), 5.00 (d, J = 8.2 Hz, NH, 1H), 
5.20 (d, J = 10.4 Hz, 2H, CH=CH
cis
H
trans
), 5.28 (d, J = 16.3 Hz, 1H, CH=CH
cis
H
trans
), 5.32 (d, 
J = 16.3 Hz, 1H, CH=CH
cis
H
trans
), 5.86-5.97 (m, 2H, CH=CH2), 6.86 (d, J = 8.3 Hz, 1H, 
C
5'
H), 6.99 (dd, J = 8.3, 2.2 Hz, 1H, C
6'
H), 7.15 (d, J = 2.2 Hz, 1H, C
2'
H). 
13
C-NMR (126 MHz, CDCl3): δ (ppm) = 28.4, 37.2, 54.5, 64.6, 67.7, 68.4, 69.1, 72.2, 72.6, 
80.1, 113.9, 117.3, 117.6, 123.1, 128.7, 129.7, 131.4, 134.4, 134.7, 153.6, 155.1, 171.7. 
 
Boc-D-Tyr(3-Cl,CH2CH2OAllyl)-OH (14) 
 
12 (1.23 g, 2.55 mmol, 1 equiv) was dissolved in MeOH/THF (1:1, 13 mL total) and Li-
OH·H2O (0.16 g, 3.83 mmol, 1.5 equiv) in H2O (6.5 mL) was added dropwise and the solu-
tion was stirred for 2 h at rt. Then, H2O (50 mL) was added and the pH was adjusted to 3 with 
1M KHSO4. The solution was extracted with EtOAc (3 × 50 mL) and the combined organic 
layers were thoroughly washed with 1 M HCl (3 × 50 mL) and brine (50 mL). The organic 
layer was dried over Na2SO4 and the solvent was removed under reduced pressure to obtain 
0.92 g (90% yield) of 14 as white solid.  
1
H-NMR (500 MHz, CDCl3, rotamers): δ (ppm) = 1.33/1.42 (2 s, 9H, (CH3)3C), 2.81-2.85 
(m, 0.3H, C
β
H
A
H
B
), 2.99 (dd, J = 14.0, 6.4 Hz, 0.7H, C
β
H
A
H
B
), 3.12 (dd, J = 14.2, 5.6 Hz, 
1H, C
β
H
A
H
B
), 3.85 (t, J = 4.9 Hz, 2H, C
ar
OCH2CH2), 4.13 (d, J = 5.6 Hz, C
ar
O(CH2)2OCH2), 
4.16 (t, J = 4.9 Hz, 2H, C
ar
OCH2), 4.34 (m, 0.3H, C
α
H), 4.53 (q, J = 6.4 Hz, 0.7H, C
α
H), 5.00 
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(d, J = 8.2 Hz, NH, 0.6H), 5.20 (d, J = 10.4 Hz, 1H, CH=CH
cis
H
trans
), 5.32 (d, J = 17.3 Hz, 
1H, CH=CH
cis
H
trans
), 5.93 (ddt, J = 16.5, 10.9, 5.6 Hz, 1H, CH=CH2), 6.43 (d, J = 7.4 Hz, 
0.3H, NH), 6.87 (d, J = 8.3 Hz, 1H, C
5'
H), 7.01 (d, J = 8.3 Hz, 1H, C
6'
H), 7.19 (br m, 1H, 
C
2'
H). 
13
C-NMR (126 MHz, CDCl3): δ (ppm) = 28.2, 28.4, 36.9, 54.4, 68.4, 69.1, 72.6, 80.5, 113.9, 
117.5, 123.1, 128.7, 129.6, 131.3, 134.6, 153.6, 155.4, 175.5. 
 
3) Synthesis of new cryptophycins  
uA[acetonide]DC (17) 
 
Unit A synthesized as previously described [3] (300 mg, 0.80 mmol, 1 equiv), unit CD (360 
mg, 0.80 mmol, 1 equiv) and 4-DMAP (25 mg, 0.2 mmol, 0.25 equiv) were placed in a round 
bottomed flask under argon atmosphere. Anhydrous THF (10 mL) was added and the solution 
was cooled down to 0 °C. Et3N (225 μL, 1.6 mmol, 2 equiv) and 2,4,6-trichlorobenzoyl chlo-
ride (255 μL, 1.6 mmol, 2 equiv) were added dropwise and the solution was stirred at 0 °C for 
3 h. Then, a 10% citric acid solution (25 mL) was added and the solution warmed up to rt. 
Solution was extracted with EtOAc (3 × 50 mL), the combined organic layers were washed 
with sat. NaHCO3 (100 mL) and brine (100 mL), dried over MgSO4 and the solvent was re-
moved under reduced pressure. The product was purified by column chromatography using 
PE/EtOAc (9:1 → 8:2) as eluent to obtain 520 mg (80% yield) of 17 as colourless oil.  
1
H-NMR (600 MHz, CDCl3): δ (ppm) = 0.90 (d, J = 6.5 Hz, 3H, uD-C
δ
H3), 0.95 (d, J = 6.5 
Hz, 3H, uD-C
δ
H3), 1.09 (d, J = 7.0 Hz, 3H, uA-C
ε
HCH3), 1.21 (s, 3H, uA-C(CH3)2), 1.23 (s, 
3H, uA-C(CH3)2), 1.46 (br s, 12H, uA-C(CH3)3 and uC-C(CH3)2), 1.52 (s, 3H, uC-C(CH3)2), 
1.57-1.61 (m, 1H, uD-C
γ
H), 1.71-1.80 (m, 2H, uD-C
β
H2), 1.92-1.97 (m, 1H, uA-C
ε
H), 2.34-
2.43 (m, 2H, uA-C
γ
H2), 3.36 (d, J = 6.6 Hz, 2H, uC-CH2NH), 3.83 (dd, J = 8.8, 2.5 Hz, 1H, 
uA-C
ζ
H), 4.23 (t, J = 7.5 Hz, 1H, CHCH2, Fmoc), 4.34 (dd, J = 10.6, 7.6 Hz, 1H, CHCH
A
H
B
, 
Fmoc), 4.37 (dd, J = 10.6, 7.6 Hz, 1H, CHCH
A
H
B
, Fmoc), 4.70 (d, J = 8.8 Hz, 1H, uA-C
η
H), 
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5.01 (dd, J = 10.1, 3.5 Hz, 1H, uD-C
α
H), 5.05 (td, J = 6.9, 4.5 Hz, 1H, uA-C
δ
H), 5.58 (d, J = 
15.6 Hz, 1H, uA-C
α
H), 5.98 (t, J = 6.6 Hz, 1H, NH), 6.58 (dt, J = 15.6, 7.3 Hz, 1H, uA-C
β
H), 
7.29-7.40 (m, 9H, uA-C
ar
H, C
ar
H, Fmoc), 7.63 (d, J = 7.5 Hz, 1H, C
ar
H, Fmoc), 7.65 (d, J = 
7.5 Hz, 1H, C
ar
H, Fmoc), 7.76 (d, J = 7.5 Hz, 2H, C
ar
H, Fmoc). 
13
C-NMR (151 MHz, CDCl3): δ (ppm) = 9.8, 21.5, 22.5, 23.1, 23.3, 25.0, 27.2, 27.3, 28.2, 
33.7, 35.6, 39.6, 44.1, 47.4, 49.4, 66.9, 71.0, 75.7, 80.3, 80.4, 82.0, 109.1, 120.0, 125.4, 125.4, 
126.4, 126.8, 127.1, 127.2, 127.7, 128.7, 128.9, 137.6, 141.3, 141.4, 141.4, 144.2, 144.2, 
157.1, 165.4, 170.9, 176.1. 
 
Seco-uA[acetonide]-DCB[OCH2CH2OCH2CH2OCH2CH2N3] (18) 
 
17 (290 mg, 0.35 mmol, 1 equiv) was dissolved in anhydrous DMF (2 mL) under argon at-
mosphere. Then, piperidine (175 μL, 1.75 mmol, 5 equiv) was added and the solution stirred 
at rt for 2 h. After this time the solvents were removed under reduced pressure. 13 (220 mg, 
0.45 mmol, 1.3 equiv) was dissolved in anhydrous CH2Cl2 (1 mL) under argon atmosphere 
and the solution was cooled down to 0 °C. Then, Et3N (160 μL, 1.12 mmol, 3.2 equiv) and 
deprotected unit ADC in anhydrous CH2Cl2 (1 mL) were added dropwise. Then, HOAt (78 
mg, 0.57 mmol, 1.6 equiv) was added as a solid. After complete dissolution, EDC·HCl (109 
mg, 0.57 mmol, 1.6 equiv), was added and the mixture stirred overnight while gradually 
warmed to rt. Then, H2O (45 ml) and EtOAc (45 mL) were added, the layers were separated 
and the organic layer was washed with 5% KHSO4 (45 mL) and saturated NaHCO3 (45 mL), 
it was dried over MgSO4 and the solvent was removed under reduced pressure. The product 
was purified by column chromatography using PE/EtOAc (3:2) as eluent to obtain 190 mg 
(51% yield) of 18 as white solid.  
1
H-NMR (600 MHz, CDCl3): δ (ppm) = 0.87 (d, J = 6.4 Hz, 3H, uD-C
δ
H3), 0.90 (d, J = 6.4 
Hz, 3H, uD-C
δ
H3), 1.12 (d, J = 6.9 Hz, 3H, uA-C
ε
HCH3), 1.15 (s, 3H, uC-C(CH3)2), 1.16 (s, 
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3H, uC-C(CH3)2), 1.37 (s, 9H, uB-C(CH3)3), 1.42 (s, 9H, uA-C(CH3)3), 1.45 (s, 3H, uA-
C(CH3)2), 1.51 (s, 3H, uA-C(CH3)2), 1.52-1.54 (m, 1H, uD-C
γ
H), 1.65-1.69 (m, 2H, uD-
C
β
H2), 1.92-1.97 (m, 1H, uA-C
ε
H), 2.35-2.42 (m, 2H, uA-C
γ
H2), 2.81 (dd, J = 14.0, 7.3 Hz, 
1H, uB-C
β
H
A
H
B
), 3.07 (dd, J = 14.0, 5.8 Hz, 1H, uB-C
β
H
A
H
B
), 3.27 (dd, J = 13.2, 5.0 Hz,  
1H, uC-CH
A
H
B
NH), 3.38 (t, J = 5.1 Hz, 2H, uB-CH2N3), 3.50 (dd, J = 13.2, 7.8 Hz, 1H, uC-
CH
A
H
B
NH), 3.67-3.69 (m, 4H, uB-CH2), 3.77-3.79 (m, 2H, uB-CH2), 3.87-3.89 (m, 3H, uB-
C
ar
OCH2CH2, uA-C
ζ
H), 4.14 (m, 2H, uB-C
ar
OCH2), 4.28 (m, 1H, uB-C
α
H), 4.69 (d, J = 8.7 
Hz, 1H, uA-C
η
H), 4.91 (dd, J = 9.6, 3.7 Hz, 1H, uD-C
α
H), 5.03 (m, 1H, uA-C
δ
H), 5.19 (d, J = 
8.1 Hz, 1H, uB-NH), 5.60 (d, J = 15.6 Hz, 1H, uA-C
α
H), 6.52 (dt, J = 15.4, 7.6 Hz, 1H, uA-
C
β
H), 6.84 (d, J = 8.3 Hz, 1H, uB-C
5’
H), 7.01 (dd, J = 8.3, 2.1 Hz, 1H, uB-C
6’
H), 7.18 (s, 1H, 
uB-C
2’
H), 7.28-7.40 (m, 5H, uA-C
ar
H). 
13
C-NMR (151 MHz, CDCl3): δ (ppm) = 9.4, 21.6, 22.5, 23.1, 23.3, 25.0, 27.1, 27.2, 28.2, 
28.4, 33.6, 35.8, 38.0, 39.6, 43.8, 47.3, 50.8, 55.9, 69.1, 69.7, 70.2, 70.9, 71.1, 71.3, 75.9, 
79.8, 80.4, 80.5, 82.0, 109.1, 113.8, 122.9, 126.5, 127.2, 128.7, 128.7, 128.8, 130.6, 131.4, 
137.5, 141.6, 153.3, 155.2, 165.2, 171.3, 171.4, 176.0. 
 
uA[diol]-uB[OCH2CH2OCH2CH2OCH2CH2N3]-Cryptophycin-52 (20) 
 
18 (165 mg, 0.16 mmol, 1 equiv) was dissolved in CH2Cl2 (1.75 mL), H2O (0.2 mL) and TFA (1.70 
mL) and the solution was stirred for 2 h at rt. The solvents were removed under reduced pressure and the 
product dried in HV overnight over KOH. The product was dissolved in DMF (10 mL) and transferred 
into a syringe. HATU (90 mg, 0.24 mmol, 1.5 equiv) and HOAt (33 mg, 0.24 mmol, 1.5 equiv) were 
dissolved in DMF (10 mL) and transferred into a second syringe. These two solutions were added to a 
stirred solution of DIPEA (84 μL, 0.48 mmol, 3equiv) in DMF (27.5 mL) at a rate of 0.01 mL/h using a 
dual channel syringe pump. Once the addition was complete, the mixture was stirred for another 2 h. 
Then, the solvent was removed, the crude dissolved with EtOAc (50 mL) and washed with saturated 
NaHCO3 (50 mL) and brine (50 mL). The organic layer was dried over MgSO4 and the solvent removed 
under reduced pressure. The product was purified by column chromatography using PE/EtOAc (1:4) as 
eluent to obtain 28 mg (21% yield) of 20 as white solid.  
 S13 
1
H-NMR (600 MHz, CDCl3): δ (ppm) = 0.86 (d, J = 6.1 Hz, 3H, uD-C
δ
H3), 0.92 (d, J = 6.1 
Hz, 3H, uD-C
δ
H3), 0.98 (s, 3H, uC-C(CH3)2), 1.00 (d, J = 7.0 Hz, 3H, uA-C
ε
HCH3), 1.13 (s, 
3H, uC-C(CH3)2), 1.52-1.66 (m, 4H, uD-C
γ
H, uD-C
β
H2, uA-C
ε
H), 2.15-2.20 (m, 1H, uA-
C
γ
H
A
H
B
), 2.66-2.70 (m, 1H, uA-C
γ
H
A
H
B
), 3.01-3.05 (m, 2H, uB-C
β
H2), 3.26 (dd, J = 13.8, 
6.1 Hz, 1H, uC-CH
A
H
B
NH), 3.30 (dd, J = 13.8, 6.5 Hz, 1H, uC-CH
A
H
B
NH), 3.38 (t, J = 5.1 
Hz, 2H, uB-CH2N3), 3.67 (m, 4H, uB-CH2), 3.74 (d, J = 8.6 Hz, 1H, uA-C
ζ
H), 3.76-3.78 (m, 
2H, uB-CH2), 3.89 (t, J = 4.9 Hz, 2H, uB-C
ar
OCH2CH2), 4.15 (t, J = 4.9 Hz, 2H, uB-
C
ar
OCH2), 4.32 (br, 2H, 2xOH), 4.56 (d, J = 8.6 Hz, 1H, uA-C
η
H), 4.83 (q, J = 6.6 Hz, 1H, 
uB-C
α
H), 4.94 (td, J = 8.0, 3.0 Hz, 1H, uA-C
δ
H), 5.11 (dd, J = 10.4, 3.4 Hz, 1H, uD-C
α
H), 
5.68 (d, J = 15.8 Hz, 1H, uA-C
α
H), 6.04 (d, J = 9.1 Hz, 1H, uB-NH), 6.29 (dt, J = 15.4, 7.2 
Hz, 1H, uA-C
β
H), 6.86 (d, J = 8.3 Hz, 1H, uB-C
5’
H), 6.98 (t, J = 6.2 Hz, uC-NH), 7.01 (dd, J 
= 8.3, 2.2 Hz, 1H, uB-C
6’
H), 7.18 (d, J = 2.2 Hz, 1H, uB-C
2’
H), 7.30-7.36 (m, 5H, uA-C
ar
H). 
13
C-NMR (151 MHz, CDCl3): δ (ppm) = 9.3, 21.3, 22.8, 23.2, 23.5, 24.9, 34.7, 35.9, 36.8, 
39.1, 42.9, 46.6, 50.8, 54.0, 69.1, 69.6, 70.1, 70.8, 71.2, 74.7, 75.9, 76.8 (overlapped with 
solvent signal), 114.2, 123.3, 126.3, 127.0, 128.5, 128.7, 129.0, 129.9, 131.2, 139.6, 140.5, 
153.6, 165.9, 171.0, 171.0, 176.3. 
HPLC-MS: TR = 9.98 min, >99% purity (λ =220 nm), m/z = 830.38 (830.37 [M+H]
+
)  
 
uB[OCH2CH2OCH2CH2OCH2CH2N3]-Cryptophycin-52 (22) 
 
The diol of 20 (20 mg, 24.1 μmol, 1 equiv) was transformed to the corresponding epoxide using a pro-
cedure previously described in the literature [4]. Final purification by column chromatography with 
PE/EtOAc (1:3) as eluent and subsequent lyophilization afforded 7 mg (36% yield over 3 steps) of 22 as 
a white solid. 
1
H-NMR (600 MHz, CDCl3): δ (ppm) = 0.77 (d, J = 7.2 Hz, 3H, uD-C
δ
H3), 0.78 (d, J = 7.2 
Hz, 3H, uD-C
δ
H3), 1.18 (d, J = 6.9 Hz, 3H, uA-C
ε
HCH3), 1.20 (s, 3H, uC-C(CH3)2, 1.23 (s, 
3H, uC-C(CH3)2), 1.33-1.37 (m, 2H, uD-C
β
H2), 1.50-1.52 (m, 1H, uD-C
γ
H), 1.89-1.92 (m, 
1H, uA-C
ε
H), 2.43 (m, 1H, uA-C
γ
H
A
H
B
), 2.75-2.78 (m, 1H, uA-C
γ
H
A
H
B
), 2.81 (dd, J = 7.1, 
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1.9 Hz, 1H, uA-C
ζ
H), 3.10 (d, J = 6.1 Hz, 2H, uB-C
β
H2), 3.27 (dd, J = 13.3, 5.0 Hz, 1H, uC-
CH
A
H
B
NH), 3.37-3.40 (m, 2H, uC-CH
A
H
B
NH, uB-CH2N3), 3.67-3.69 (m, 5H, uA-C
η
H, uB-
CH2), 3.77-3.79 (m, 2H, uB-CH2), 3.90 (t, J = 4.9 Hz, 2H, uB-C
ar
OCH2CH2), 4.17 (t, J = 4.9 
Hz, 2H, uB-C
Ar
OCH2), 4.85-4.87 (m, 1H, uB-C
α
H), 4.89-4.93 (m, 1H, uA-C
δ
H), 5.04 (dd, J = 
10.7, 3.7 Hz, 1H, uD-C
α
H), 5.73 (d, J = 8.7 Hz, uB-NH), 5.78 (d, J = 15.5 Hz, uA-C
α
H), 6.46 
(dt, J = 15.5, 7.5 Hz, uA-C
β
H), 6.88 (d, J = 8.4 Hz, 1H, uB-C
5’
H), 6.97 (t, J = 7.0 Hz, uC-
NH), 7.05 (dd, J = 8.4, 2.2 Hz, 1H, uB-C
6’
H), 7.21 (d, J = 2.2 Hz, 1H, uB-C
2’
H), 7.24-7.25 
(m, 2H, uA-C
ar
H), 7.30-7.36 (m, 3H, uA-C
ar
H). 
13
C-NMR (151 MHz, CDCl3): δ (ppm) = 13.5, 21.0, 23.0, 23.1, 23.7, 24.7, 34.3, 35.9, 39.1, 
39.3, 43.0, 46.5, 50.9, 54.2, 59.6, 64.3, 69.2, 69.7, 70.2, 70.8, 70.9, 71.3, 76.8 (overlapped 
with solvent signal), 114.2, 123.3, 125.8, 127.0, 128.5, 128.8, 129.8, 131.2, 136.8, 138.4, 
153.7, 165.5, 170.6, 170.7, 176.6. 
HPLC-MS: TR = 11.25 min, >99% purity (λ =220 nm), m/z = 812.37 (812.36 [M+H]
+
)  
HRMS (ESI-MS): m/z calculated for C41H55ClN5O10 [M+H]
+
 812.3632; found 812.3626 
 
Seco-uA[acetonide]-DCB[OCH2CH2OCH2CHCH2] (19) 
 
17 (500 mg, 0.62 mmol, 1 equiv) was dissolved in anhydrous DMF (4 mL) under argon at-
mosphere. Then, piperidine (305 μL, 3.1 mmol, 5 equiv) was added and the solution stirred at 
rt for 2 h. After this time the solvents were removed under reduced pressure. 14 (320 mg, 0.81 
mmol, 1.3 equiv) was dissolved in anhydrous CH2Cl2 (2 mL) under argon atmosphere and the 
solution was cooled down to 0 °C. Then, Et3N (275 μL, 1.97 mmol, 3.2 equiv) and deprotect-
ed unit ADC in anhydrous CH2Cl2 (2 mL) were added dropwise. Then, HOAt (135 mg, 0.99 
mmol, 1.6 equiv) was added as a solid. After complete dissolution, EDC·HCl (190 mg, 0.99 
mmol, 1.6 equiv), was added and the mixture stirred overnight while gradually warmed to rt. 
Then, H2O (75 ml) and EtOAc (75 mL) were added, the layers were separated and the organic 
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layer was washed with 5% KHSO4 (75 mL) and saturated NaHCO3 (75 mL), it was dried over 
MgSO4 and the solvent was removed under reduced pressure. The product was purified by 
column chromatography using PE/EtOAc (7:3) as eluent to obtain 350 mg (59% yield) of 19 
as white solid.  
1
H-NMR (600 MHz, CDCl3): δ (ppm) = 0.84 (d, J = 6.3 Hz, 3H, uD-C
δ
H3), 0.91 (d, J = 6.3 
Hz, 3H, uD-C
δ
H3), 1.08 (s, 3H, uC-C(CH3)2), 1.11 (d, J = 7.0 Hz, 3H, uA-C
ε
HCH3), 1.17 (s, 
3H, uC-C(CH3)2), 1.34 (s, 9H, uB-C(CH3)3), 1.43 (s, 3H, uA-C(CH3)2), 1.47 (s, 9H, uA-
C(CH3)3), 1.48 (s, 3H, uA-C(CH3)2), 1.66-1.74, m, 3H, uD-C
γ
H, uD-C
β
H2), 1.85-1.90 (m, 1H, 
uA-C
ε
H), 2.27-2.33 (m, 1H, uA-C
γ
H2), 2.50-2.54 (m, 1H, uA-C
γ
H2), 2.83 (dd, J = 13.6, 9.9 
Hz, 1H, uB-C
β
H
A
H
B
), 3.22-3.28 (m, 2H, uB-C
β
H
A
H
B
, uC-CH
A
H
B
NH), 3.61 (dd, J = 13.4, 8.3 
Hz, 1H, uC-CH
A
H
B
NH), 3.81-3.83 (m, 3H, C
ar
OCH2CH2, uA-C
ζ
H), 4.12 (dt, J = 5.7, 1.4 Hz, 
2H, C
ar
O(CH2)2OCH2), 4.14 (t, J = 5.0 Hz, 2H, C
ar
OCH2), 4.41 (q, J = 9.1 Hz, 1H, uB-C
α
H), 
4.70 (d, J = 8.9 Hz, 1H, uA-C
η
H), 4.89 (dd, J = 10.2, 3.0 Hz, 1H, uD-C
α
H), 5.08 (t, J = 8.5 
Hz, 1H, uA-C
δ
H), 5.19 (dq, J = 10.3, 1.4 Hz, 1H, CH=CH
trans
H
cis
), 5.31 (dq, J = 17.3, 1.6 Hz, 
1H, CH=CH
trans
H
cis
), 5.68 (d, J = 15.5 Hz, 1H, uA-C
α
H), 5.79 (d, J = 8.7 Hz, 1H, uB-NH), 
5.92 (ddt, J = 17.3, 10.8, 5.6 Hz, 1H, CH=CH2), 6.74 (ddd, J = 15.2, 8.9, 5.3 Hz, 1H, uA-
C
β
H), 6.85 (d, J = 8.3 Hz, 1H, uB-C
5’
H), 7.09 (dd, J = 8.5, 2.1 Hz, 1H, uB-C
6’
H), 7.13-7.15 
(m, 1H, uC-NH), 7.26-7.37 (m, 6H, uB-C
2’
H, uA-C
ar
H). 
13
C-NMR (151 MHz, CDCl3): δ (ppm) = 9.7, 21.3, 22.0, 23.3, 24.9, 27.2, 27.3, 28.4, 28.4, 
34.9, 35.7, 37.7, 39.5, 44.0, 47.6, 56.3, 60.5, 68.4, 69.2, 70.5, 72.6, 75.6, 79.6, 80.2, 80.5, 
82.0, 109.1, 114.0, 117.3, 122.9, 125.9, 126.7, 128.6, 128.9, 131.4, 131.6, 134.8, 137.7, 142.1, 
153.2, 155.9, 166.0, 170.9, 172.0, 175.6. 
 
uA[diol]-uB[OCH2CH2OCH2CHCH2]-Cryptophycin-52 (21) 
 
19 (310 mg, 0.32 mmol, 1 equiv) was dissolved in CH2Cl2 (3. 5 mL), H2O (0.35 mL) and TFA (3.5 mL) 
and the solution was stirred for 2 h at rt. The solvents were removed under reduced pressure and the 
product dried in HV overnight over KOH. The product was dissolved in DMF (16.7 mL) and transferred 
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into a syringe. HATU (182 mg, 0.48 mmol, 1.5 equiv) and HOAt (65 mg, 0.48 mmol, 1.5 equiv) were 
dissolved in DMF (16.7 mL) and transferred into a second syringe. These two solutions were added to a 
stirred solution of DIPEA (168 μL, 0.96 mmol, 3 equiv) in DMF (15 mL) at a rate of 0.01 mL/h using a 
dual channel syringe pump. Once the addition was complete, the mixture was stirred for another 2 h. 
Then, the solvent was removed, the crude dissolved with EtOAc (100 mL) and washed with saturated 
NaHCO3 (100 mL) and brine (100 mL). The organic layer was dried over MgSO4 and the solvent was 
removed under reduced pressure. The product was purified by column chromatography using 
PE/EtOAc (1:4) as eluent to obtain 60 mg (25% yield) of 21 as white solid. 
1
H-NMR (600 MHz, CDCl3): δ (ppm) = 0.85 (d, J = 6.6 Hz, 3H, uD-C
δ
H3), 0.91 (d, J = 6.6 
Hz, 3H, uD-C
δ
H3), 0.97 (d, J = 7.0 Hz, 3H, uA-C
ε
HCH3), 1.14 (s, 3H, uC-C(CH3)2), 1.21 (s, 
3H, uC-C(CH3)2), 1.41-1.47 (m, 2H, uA-C
ε
H, uD-C
β
H2), 1.60-1.64 (m, 1H, uD-C
γ
H), 1.74-
1.79 (m, 1H, uD-C
β
H2), 2.18-2.24 (m, 1H, uA-C
γ
H2), 2.39-2.43 (m, 1H, uA-C
γ
H2), 2.90 (dd, J 
= 14.6, 9.3 Hz, 1H, uB-C
β
H
A
H
B
), 3.08 (dd, J = 14.6, 4.8 Hz, 1H, uB-C
β
H
A
H
B
), 3.13 (dd, J = 
13.5, 3.9 Hz, 1H, uC-CH
A
H
B
NH), 3.33 (dd, J = 13.5, 8.2 Hz, 1H, uC-CH
A
H
B
NH), 3.50 (br, 
1H, uA-OH), 3.67 (br, 1H, uA-OH), 3.75 (d, J = 8.3 Hz, 1H uA-C
ζ
H), 3.81 (t, J = 4.9 Hz, 2H, 
C
ar
OCH2CH2), 4.09-4.12 (m, 4H, C
ar
O(CH2)2OCH2, C
ar
OCH2), 4.53 (d, J = 8.3 Hz, 1H, uA-
C
η
H), 4.68 (td, J = 8.2, 4.9 Hz, 1H, uB-C
α
H), 4.85 (dd, J = 10.1, 3.6 Hz, 1H, uD-C
α
H), 5.03-
5.06 (m, 1H, uA-C
δ
H), 5.18 (dq, J = 10.4, 1.5 Hz, 1H, CH=CH
trans
H
cis
), 5.30 (dq, J = 17.4, 1.7 
Hz, 1H, CH=CH
trans
H
cis
), 5.72 (d, J = 15.2 Hz, 1H, uA-C
α
H), 5.91 (ddt, J = 17.2, 10.8, 5.5 Hz, 
1H, CH=CH2), 6.18 (d, J = 7.8 Hz, 1H, uB-NH), 6.68 (ddd, J = 15.1, 10.8, 4.2 Hz, 1H, uA-
C
β
H), 6.82 (d, J = 8.4 Hz, 1H, uB-C
5’
H), 7.00 (dd, J = 8.4, 2.1 Hz, 1H, uB-C
6’
H), 7.16 (d, J = 
2.1 Hz, 1H, uB-C
2’
H), 7.24-7.32 (m, 6H, uA-C
ar
H, uC-NH). 
13
C-NMR (151 MHz, CDCl3): δ (ppm) = 9.7, 21.7, 22.9, 23.1, 23.1, 24.9, 35.3, 36.2, 38.1, 
39.7, 42.8, 46.6, 54.7, 68.4, 69.1, 71.2, 72.5, 74.9, 75.8, 76.6, 114.0, 117.3, 123.1, 124.5, 
127.0, 128.2, 128.3, 128.7, 130.4, 130.9, 134.7, 140.9, 142.7, 153.5, 165.7, 170.6, 170.9, 
177.6. 
HPLC-MS: TR = 10.35 min, >99% purity (λ =220 nm), m/z = 757.35 (757.35 [M+H]
+
)  
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uB[OCH2CH2OCH2CHCH2]-Cryptophycin-52 (23) 
 
The diol of 21 (40 mg, 52.9 μmol, 1 equiv) was transformed to the corresponding epoxide using a pro-
cedure previously described in the literature [4].
 
Final purification by column chromatography with 
PE/EtOAc (1:2) as eluent and subsequent lyophilization afforded 24 mg (61% yield over 3 steps) of 23 
as a white solid. 
1
H-NMR (600 MHz, CDCl3): δ (ppm) = 0.82 (d, J = 6.5 Hz, 3H, uD-C
δ
H3), 0.84 (d, J = 6.5 
Hz, 3H, uD-C
δ
H3), 1.14 (d, J = 6.9 Hz, 3H, uA-C
ε
HCH3), 1.15 (s, 3H, uC-C(CH3)2), 1.21 (s, 
3H, uC-C(CH3)2), 1.28-1.32 (m, 1H, uD-C
γ
H), 1.62-1.73 (m, 2H, uD-C
β
H2), 1.75-1.81 (m, 
1H, uA-C
ε
H), 2.41-2.47 (m, 1H, uA-C
γ
H2), 2.55-2.59 (m, 1H, uA-C
γ
H2), 2.92 (dd, J = 7.5, 2.0 
Hz, 1H, uA-C
ζ
H), 3.02 (dd, J = 14.5, 7.7 Hz, 1H, uB-C
β
H
A
H
B
), 3.08 (m, 2H, uB-C
β
H
A
H
B
, uC-
CH
A
H
B
NH), 3.40 (dd, J = 13.6, 8.6 Hz, 1H, uC-CH
A
H
B
NH), 3.68 (d, J = 2.0 Hz, 1H, uA-
C
η
H), 3.83 (t, J = 4.9 Hz, C
ar
OCH2CH2), 4.12 (dt, J = 5.6, 1.5 Hz, 2H, C
ar
O(CH2)2OCH2), 
4.15 (t, J = 4.9 Hz, 2H, C
ar
OCH2), 4.72 (td, J = 7.7, 4.9 Hz, 1H, uB-C
α
H), 4.83 (dd, J = 10.2, 
3.5 Hz, 1H, uD-C
α
H), 5.17-5.21 (m, 2H, uA-C
δ
H, CH=CH
trans
H
cis
), 5.32 (dq, J = 17.4, 1.7 Hz, 
1H, CH=CH
trans
H
cis
), 5.63 (d, J = 7.8 Hz, uB-NH), 5.71 (dd, J = 15.1, 1.8 Hz, 1H, uA-C
α
H), 
5.93 (ddt, J = 17.3, 10.8, 5.6 Hz, 1H, CH=CH2), 6.75 (ddd, J = 15.0, 10.6, 4.3 Hz, 1H, uA-
C
β
H), 6.85 (d, J = 8.4 Hz, 1H, uB-C
5’
H), 7.01 (dd, J = 8.4, 2.2 Hz, 1H, uB-C
6’
H), 7.18 (d, J = 
2.2 Hz, 1H, uB-C
2’
H), 7.21 (dd, J = 8.9, 3.5 Hz, 1H, uC-NH), 7.23-7.25 (m, 2H, uA-C
ar
H), 
7.31-7.37 (m, 3H, uA-C
ar
H). 
13
C-NMR (151 MHz, CDCl3): δ (ppm) = 13.7, 21.4, 22.9, 23.0, 24.7, 35.5, 37.0, 39.5, 40.8, 
42.9, 46.6, 54.5, 59.2, 63.2, 68.4, 69.2, 71.3, 72.6, 76.0, 114.2, 117.4, 123.4, 124.8, 125.7, 
128.3, 128.7, 128.9, 130.0, 131.0, 134.7, 136.9, 141.9, 153.7, 165.1, 170.5, 170.6, 178.1. 
HPLC-MS: TR = 11.53 min, 98% purity (λ =220 nm), m/z = 739.33 (739.34 [M+H]
+
)  
HRMS (ESI-MS): m/z calculated for C40H52ClN2O9 [M+H]
+
 739.3356; found 739.3359 
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uB[OCH2CH2OH]-Cryptophycin-52 (24) 
 
23 (5 mg, 6.8 μmol, 1 equiv) and Pd(PPh3)4 (0.8 mg, 0.68 μmol, 10%) were dissolved with anhydrous 
and degassed CH2Cl2 (1 mL). Phenylsilane (4.2 μL, 34 μmol, 5 equiv) was added and the solution was 
stirred at rt for 7 h. Then, the solvent was removed by bubbling air and the product was purified by col-
umn chromatography using PE/EtOAc (1:2) as eluent and subsequent lyophilization afforded 2 mg 
(42% yield) of 24 as white solid. 
1
H-NMR (600 MHz, CDCl3): δ (ppm) = 0.83 (d, J = 6.4 Hz, 3H, uD-C
δ
H3), 0.84 (d, J = 6.4 
Hz, 3H, uD-C
δ
H3), 1.14-1.15 (m, 6H, uA-C
ε
HCH3, uC-C(CH3)2), 1.22 (s, 3H, uC-C(CH3)2), 
1.30-1.34 (m, 1H, uD-C
γ
H), 1.66-1.74 (m, 2H, uD-C
β
H2), 1.77-1.80 (m, 1H, uA-C
ε
H), 2.14-
2.18 (br s, 1H, OH), 2.42-2.48 (m, 1H, uA-C
γ
H2), 2.56-2.59 (m, 1H, uA-C
γ
H2), 2.92 (d, J = 
7.3 Hz, 1H, uA-C
ζ
H), 3.05-3.13 (m, 3H, uB-C
β
H2, uC-CH
A
H
B
NH), 3.40 (dd, J = 13.6, 8.3 Hz, 
1H, uC-CH
A
H
B
NH), 3.68 (s, 1H, uA-C
η
H), 3.98 (s, 2H, C
ar
OCH2CH2), 4.12 (t, J = 4.1 Hz, 
2H, C
ar
OCH2), 4.75 (q, J = 6.5 Hz, 1H, uB-C
α
H), 4.83 (dd, J = 10.0, 3.7 Hz, 1H, uD-C
α
H), 
5.19-5.21 (m, 1H, uA-C
δ
H), 5.44 (d, J = 7.8 Hz, uB-NH), 5.72 (d, J = 15.2 Hz, 1H, uA-C
α
H), 
6.76 (ddd, J = 15.0, 10.5, 4.4 Hz, 1H, uA-C
β
H), 6.86 (d, J = 8.2 Hz, 1H, uB-C
5’
H), 7.04 (d, J 
= 8.2 Hz, 1H, uB-C
6’
H), 7.18-7.25 (m, 3H, uB-C
2’
H, uA-C
ar
H), 7.34-7.38 (m, 3H, uA-C
ar
H). 
HPLC-MS: TR = 10.61 min, >99% purity (λ =220 nm), m/z = 699.31 (699.30 [M+H]
+
)  
HRMS (ESI-MS): m/z calculated for C37H48ClN2O9 [M+H]
+
 699.3043; found 699.3047 
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1) General methods 
All reactions requiring anhydrous conditions were performed under argon atmosphere. 
DMF was dried over 4 Å molecular sieves, CH2Cl2 was distilled from CaH2, THF was 
distilled from sodium/benzophenone. All the other chemicals and solvents (HPLC-grade 
or reagent-grade quality), unless otherwise stated, were purchased from commercial 
sources and used without further purification. Silica for flash chromatography was 
purchased from Macherey-Nagel 40-63 μM (230-400 mesh). Reactions were monitored 
by thin layer chromatography using aluminium-backed plates coated with silica gel 60 
F254 from Merck; visualization was accomplished with UV light or staining with 
potassium permanganate or cerium molybdate solution.   
High performance liquid chromatography - mass spectrometry 
HPLC-MS was conducted using an Agilent 1200 series consisting of an autosampler, 
degasser, binary pump, column oven and diode array detector coupled to an Agilent 6220 
accurate-mass TOF LC/MS. A Phenomenex Luna® 3 µm C18(2) 100 Å (100 mm x 2 
mm) was used as column.  
Eluent A: H2O/CH3CN/HCO2H = 95/5/0.1 and eluent B: H2O/CH3CN/HCO2H = 
5/95/0.1. 
Flow rate: 300 µL/min  
 0 min  100% A  0% B 
 10.0 min 2% A  98% B 
 11.0 min 2% A  98% B 
 11.5 min 100% A 0% B 
 15.0 min 100% A 0% B 
High resolution mass spectrometry 
High resolution mass spectra were recorded on an Agilent 6220 accurate-mass TOF 
LC/MS. Samples were injected through an Agilent 1200 series. Same solvents and 
column than HPLC-MS were used and a linear gradient from 0 to 98% B at 250 µL/min 
over 4 minutes was employed.  
The mass spectrometer was externally calibrated using Agilent tuning mix prior to 
measurement.   
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Preparative reversed phase - high performance liquid chromatography 
Preparative RP-HPLC was performed on a MERCK-HITACHI unit (controller: D-7000, 
pump: L7150, detector: L7420, UV-absorption measured at λ = 220 nm). 
Eluent A: H2O/CH3CN/TFA = 95/5/0.1 and eluent B: H2O/CH3CN/TFA = 5/95/0.1 
Method P1:  
Column: Macherey-Nagel Nucleosil C18 (250 mm x 21 mm, 10 μm particle size) 
Flow rate: 10 mL/min 
0-2 min  100% A 0% B 
35 min   0% A   100% B 
40 min   0% A  100% B 
45 min   100% A  0% B 
Method P2: 
Column: Macherey-Nagel Nucleosil C18 (250 mm x 21 mm, 10 μm particle size) 
Flow rate: 10 mL/min 
0-5 min 100% A 0% B 
50 min  0% A  100% B 
55 min  0% A  100% B 
60 min  100% A 0% B 
Method P3: 
Column: Macherey-Nagel Nucleosil C18 (250 mm x 10 mm, 7 μm particle size) 
Flow rate: 4 mL/min 
0-15 min 100% A 0% B 
60 min  0% A  100% B 
65 min  0% A  100% B 
70 min  100% A 0% B 
Method P4: 
Column: Macherey-Nagel Nucleosil C18 (250 mm x 10 mm, 7 μm particle size) 
Flow rate: 4 mL/min 
0-15 min 100% A 0% B 
75 min  0% A  100% B 
80 min  0% A  100% B 
85 min  100% A 0% B 
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UPLC-HRMS conditions for plasma stability studies  
Samples were analyzed on a system consisting of a Dionex Ultimate 3000 RS Pump 
coupled with (a) Dionex Ultimate 3000 RS from Thermo Scientific (Bremen, Germany) 
autosampler or (b) PAL LSI from CTC Analytics AG (Zwingen, Switzerland) 
autosampler. UPLC Peptide BEH C18 (50 mm x 2.1 mm, 1.7 µm, 130 Å) column from 
Waters (Wexford, Ireland) at 40 °C was used for chromatographic separation at a flow 
rate of 400 µL/min with a linear gradient composed of mobile phase A (0.1% formic acid 
in water) and B (0.1% formic acid in CH3CN). A volume of (a) 2 µL or (b) 5 µL was 
injected.  
Gradient:  
 0 min  99.5% A  0.5% B 
 4.0 min 5% A  95% B 
 5.0 min 5% A  95% B 
 5.1 min 99.5% A 0.5% B 
 6.0 min 99.5% A 0.5% B 
All analyses were performed on a Q-Exactive Orbitrap™ mass spectrometer (Thermo 
Scientific) in ESI positive full scan/data-dependent MS/MS (FS-dd-MS/MS). Each cycle 
contains four scan events: Full Scan with m/z range (a) 150-1600 or (b) 200-2000 and 
resolution 35,000 FWHM at 200 m/z, mass accuracy: 5 ppm, followed by three MS/MS 
fragmentation scans with resolution 17,500 FWHM at 200 m/z over the three most 
abundant ions (Top N = 3) of the full-MS spectrum. The IS warfarin was detected in FS 
using the [M+H]+ at m/z: 309.1121. Analysis of data was performed with XCalibur 
software. (a) was used for mouse plasma stability while (b) was used for human plasma 
stability. 
HPLC-MS conditions for pharmacokinetic analysis  
Samples were analyzed using a HPLC (Nexera, Shimadzu) connected to an Orbitrap 
Qexactive Focus (Thermo Scientific). A Jupiter C18 300 Å (50 mm x 2 mm) 5 µm particle 
size was used as column.  
Eluent A: H2O/CH3CN/HCO2H = 90/10/0.1 and eluent B: CH3CN/HCO2H 99.9/0.1. 
Flow rate: 400 µL/min  
 0 min   60% A  40% B 
 2.5 min 40% A  60% B 
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 2.6 min 0% A   100% B 
 4.0 min 0% A  100% B 
 4.1 min 60% A  40% B 
 6.0 min 60% A  40% B  
HPLC-MS conditions for cathepsin B cleavage studies  
Samples were analyzed using a HPLC (Prominence, Shimadzu) connected to a triple 
quadrupole mass spectrometer (API4000, Sciex). A Jupiter C18 300 Å (50 mm x 2 mm) 
5 µm particle size was used as column.  
Eluent A: H2O/CH3CN/HCO2H = 90/10/0.1 and eluent B: ACN/HCO2H 99.9/0.1. 
Flow rate: 200 µL/min  
 0 min   60% A  40% B 
 5.0 min 60% A  40% B 
 5.1 min 0% A   100% B 
 7.0 min 0% A  100% B 
 7.1 min 60% A  40% B 
 10 min  60% A  40% B  
NMR spectroscopy 
NMR spectra were recorded on a Bruker Avance 500 or Avance 500HD spectrometer 
(1H: 500 MHz) at 298 K. Chemical shifts were referenced to residual nondeuterated 
solvent signal (CDCl3: 1H: 7.26 ppm). Coupling constants (J) are reported in Hz with the 
following abbreviations used to indicate splitting: s = singlet, t = triplet, m = multiplet.  
Photo spectrophotometer  
Photo spectrometry was recorded in a UV-3100 PC from VWR®. 
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2) Synthesis of octreotide-Cy5.5 conjugate 
 
Scheme S1. Synthesis of octreotide-cy5.5 conjugate 10. Reagents and conditions: a) 
PyBOP (2 eq), HOBtꞏH2O (2.25 eq), DIPEA (2.5 eq), DMF, RT, 4 h; b) CuSO4ꞏ5H2O 
(0.6 eq), sodium ascorbate (0.4 eq), DMF/H2O (1:1), 40 ºC, 24 h.    
 
Synthesis of N3-PEG4-Val-Cit-Gly-Pro-Cy5.5 (9): 
 
Cy5.5 (7.5 mg, 9.97 µmol, 1 eq), 5 (14 mg, 19.96 µmol, 2 eq), PyBOP (10.4 mg, 19.98 
µmol, 2 eq) and HOBt∙H2O (3.4 mg; 22.2 µmol; 2.25 eq) were placed under argon 
atmosphere and dissolved with anhydrous DMF (0.5 mL). DIPEA (8.7 µL, 49.94 µmol, 
5 eq) was added and the reaction mixture was stirred at RT for 4 h. Then, the solution was 
directly purified by RP-HPLC (method P3). Freeze-drying of fractions containing the 
product afforded 9 (14.4 mg, 98% yield) as blue powder. 
HPLC-MS: tR = 7.93 min, >99% purity (λ = 220 nm), m/z = 1364.91 (1364.81 [M]+); 682.99 
(682.91 [M+H]2+) 
HRMS (ESI-MS): m/z calculated for C75H107N13O11 [M+H]2+ 682.9101; found 682.9130 
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Synthesis of 10: 
 
Azide 9 (4.5 mg, 3.05 µmol, 1 eq), alkyne 6 (4.1 mg, 3.38 µmol, 1.1 eq), CuSO4ꞏ5H2O 
(0.5 mg, 0.6 eq) and sodium ascorbate (0.24 mg, 0.4 eq) were placed under argon 
atmosphere and dissolved with a degassed solution of DMF/H2O (1:1, 0.5 mL). The 
solution was stirred for 24 h at 40 ºC and was directly purified by RP-HPLC (method P3). 
Freeze-drying of desired fractions afforded 10 (6 mg, 73% yield) as blue powder. 
HPLC-MS: tR = 6.99 min, >99% purity (λ = 220 nm), m/z = 1232.22 (1232.14 [M+H]2+); 821.82 
(821.76 [M+2H]3+); 616.62 (616.58 [M+3H]4+) 
HRMS (ESI-MS): m/z calculated for C129H178N23O22S2 [M+2H]3+ 821.7647; found 821.7670; 
calculated for C129H179N23O22S2 [M+3H]4+ 616.5754; found 616.5768 
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3) Synthesis of PEG spacer 
tert-Butyl-15-hydroxy-4,7,10,13-tetraoxapentadecanoate (11): 
 
To a solution of tetraethyleneglycol (40.61 mL, 45.64 g, 235 mmol) in anhydrous THF 
(125 mL) a piece of sodium (1/4 cm) was added. After the sodium had reacted completely, 
tert-butylacrylate (11.98 mL, 10.57 g, 82.5 mmol) was added dropwise over 20 min and 
the resulting solution was stirred at RT overnight. The pH was adjusted to 7-8 with NaOH 
solution (1 N) and the solvents were removed in vacuum. The residue was dissolved in 
sat. NaCl solution (75 mL) and extracted with EtOAc (3 x 100 mL). The combined 
organic layers were dried over MgSO4 and the solvent was removed under reduced 
pressure to obtain 11 (21.87 g, 82% yield) as colorless oil. 
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.44 (s, 9H, C(CH3)3), 2.50 (t, J = 6.6 Hz, 2H, 
CH2COOtBu), 3.59-3.73 (m, 18H, OCH2).  
 
tert-Butyl 15-Azido-4,7,10,13-tetraoxapentadecanoate (12): 
 
11 (1.50 g, 4.65 mmol, 1 eq) was dissolved in anhydrous THF (10 mL) and the resulting 
solution was cooled to 0°C. Methanesulfonyl chloride (0.54 mL, 6.98 mmol, 1.5 eq) and 
triethylamine (0.97 mL, 6.98 mmol, 1.5 eq) were added dropwise and the solution was 
stirred for 30 min at 0 °C and then overnight at RT. NaHCO3 (0.27 g, 3.20 mmol, 0.7 eq) 
and NaN3 (0.45 g, 6.98 mmol, 1.5 eq) were added with dist. water (10.5 mL) to the 
mixture and the resulting solution was stirred for 20 min at RT. THF was removed in 
vacuum and the remaining solution was stirred at 80 °C for 4 h. After cooling down, the 
mixture was extracted with DCM (3 x 30 mL), the combined organic layers were dried 
over MgSO4 and the solvent was removed under reduced pressure. The crude was purified 
by column chromatography using PE/EtOAc (1:1) as eluent to obtain 12 (0.74 g; 46% 
yield) as colorless oil. 
1H-NMR (500 MHz, CDCl3): δ (ppm) = 1.44 (s, 9H, C(CH3)3), 2.49 (t, 2H, J = 6.6 Hz, 
CH2COOtBu), 3.38 (t, 2H, J = 5.1 Hz, CH2N3), 3.59-3.68 (m, 14H), 3.70 (t, 2H, J = 6.6 
Hz, CH2CH2COOtBu). 
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15-Azido-4,7,10,13-tetraoxapentadecanoic acid (13): 
 
12 (0.22 g; 0.63 mmol) was dissolved in dry DCM (5 mL) and H2O (0.25 mL). Then, 
TFA (5 mL) was added and the solution was stirred at RT for 1.5 h. The solvents were 
removed under reduced pressure and the product was coevaporated with diethyl ether (2 
x 10 mL) to obtain 13 (0.18 g, 98% yield) as colorless oil.  
1H-NMR (500 MHz, CDCl3): δ (ppm) = 2.65 (t, 2H, J = 6.1 Hz, CH2COOH), 3.40 (t, 
2H, J = 5.0 Hz, CH2N3), 3.64-3.70 (m, 14H), 3.78 (t, 2H, J = 6.1 Hz, CH2CH2COOH). 
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4) NMR, HPLC (λ = 220 nM) and mass spectra 
1: HPLC-MS 
 
 
2: HPLC-MS 
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4: HPLC-MS and HRMS  
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5: HPLC-MS and HRMS  
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6: HPLC-MS and HRMS  
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7: HPLC-MS and HRMS 
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8: HPLC-MS and HRMS  
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9: HPLC-MS and HRMS 
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10: HPLC-MS and HRMS 
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11: 1H-NMR 
 
 
12: 1H-NMR 
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13: 1H-NMR 
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5) Confocal microscopy  
 
Figure S1. Confocal microscopy images from conjugate 10 in SSTR2 positive cell line 
AtT20 in absence (left) or 100-fold excess octreotide (middle), and in SSTR2 negative 
A549 cell line (right).  
 
6) In vivo experiments 
Animal experiments were approved by the Committee for Animal Experiments of the 
District of Southern Finland (ESAVI/6285/04.10.07/2014). 
 
Implantation of tumors 
For in vivo tumor targeting and antitumor efficacy experiments, three million 
AtT20/D16v-F2 murine pituitary tumor cells in 100 µL PBS/Matrigel (v/v) were 
xenografted in the right flank of four-weeks-old female BALB/c nude mice 
(BALB/cAnNRj-Foxn1nu/nu, Janvier Labs). The experiments started around 15 days after 
implantation, when the animals started to show physical signs of the hormone releasing 
tumor. 
 
S22 
In vivo antitumor efficacy  
Animals bearing AtT20 tumors were randomized in three treatment groups (n=9) and 
injected intravenously with 5 mg/kg of conjugate 8 in 2% DMSO in water or a mix of 
unconjugated octreotide and cryptophycin in the respective molar concentration. 
Treatment was given once a week for a total of three weeks. Vehicle treatment was used 
as control. Mice were weighed, and the tumor sizes were monitored with an electronic 
caliper. Tumor volume was calculated using the ellipsoid formula  = /6ꞏ𝑥ꞏ𝑦ꞏ𝓏.
 
Figure S3. In vivo antitumor efficacy of conjugate 8 compared to vehicle and 
unconjugated mix of cryptophycin and octreotide (left), and body weight quantification 
during treatment (right).  
 
  
 
  
